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Amyotrophic  lateral  sclerosis  (ALS)  is  a  devastating  disease 
characterized by the progressive degeneration of motor neurons. Dominantly-
inherited  mutations  to  the  antioxidant  enzyme  Cu,Zn  superoxide  dismutase 
(SOD1) cause 3-6% of all ALS cases. The complete mechanism behind the 
toxicity of mutant SOD1 remains unclear, although significant evidence points 
to  aberrant  or  incomplete  metal-binding  having  a  role  in  a  toxic  gain-of-
function.  However,  the  relevance  of  the  metal-binding  of  SOD1  to  mutant-
SOD1-linked ALS remains controversial. Direct assessments of protein metal-
binding from transgenic, SOD1-overexpressing rodent models of the disease 
are difficult to acquire due to the non-covalent nature of the interaction. The 
relatively  small  amount  of  disease-afflicted  spinal  cord  tissue  in  which  the 
motor neurons reside compounds the difficulty of measuring the protein metal 
binding of SOD1 from transgenic mice. This dissertation addresses the metals 
bound  to  SOD1  throughout  the  disease  course  in  transgenic mice  using  a 
novel mass spectrometry assay. The methodology developed here offers the 
first detailed examination of partially unfolded intermediates of SOD1 present 
in the spinal cord of pre-symptomatic, symptomatic, and end-stage transgenic 
mice  overexpressing  the  ALS-associated  SOD1  mutation  G93A  (glycine 
mutated  to  alanine  at  position  93).  These  results  were  compared  to  age-matched transgenic mice expressing wild-type SOD1 that do not develop ALS 
symptoms.  
To extract SOD1 from relevant spinal cord tissue, a 300 μm necropsy 
punch was used to remove a small piece of tissue from the ventral or dorsal 
gray  matter  of  a  1  mm-thick  slice  of  spinal  cord.  Physiological  salts  that 
interfere with electrospray mass spectrometry  were removed by binding the 
proteins to a C4 Ziptip®, a pipette tip containing hydrophobic, reversed-phase 
packing  material.  Washing  the  Ziptip-bound  proteins  with  water  eliminated 
interfering  salts.  Bound  proteins  could  then  be  eluted  into  a  mass 
spectrometer  with  low  concentrations  of  acetonitrile  plus  formic  acid. 
Electrospray  ionization  conditions  were  determined  that  could  keep  both 
copper and zinc bound to SOD1. Using a high-resolution Fourier transform-ion 
cyclotron  resonance  mass  spectrometer,  we  used  the  assay  to  collect 
isotopically-resolved  protein  mass  data.  Theoretical  protein  isotope 
distributions  were  calculated  from  the  empirical  formulas  of  SOD1  and 
matched  to  the  experimental  data  with  a  least  squares  fitting  algorithm  to 
determine the multiple intermediates of SOD1 present.  
Spinal  cord  tissue,  wild-type  in  particular,  was  notable for containing 
significantly more one-metal SOD1 than any other tissue, despite having 3-fold 
less  SOD1  than  liver.  We  quantitatively  compared  the  levels  of  soluble, 
partially  unfolded  intermediates  of  SOD1  from  wild-type  and  G93A  SOD1 
spinal cords. Wild-type mouse spinal cord contained significantly more of all of 
the partially unfolded intermediates copper-deficient SOD1, disulfide reduced 
SOD1,  and  apo  SOD1.  The  amount  of  zinc-containing  SOD1  was 
exceptionally high in wild-type mice, comprising 60% of the total SOD1 in wild-
type spinal cord. The larger amounts of these SOD1 intermediates in wild-type 
transgenic mice indicate that they are not directly responsible for toxicity in 
vivo. However, copper-containing, zinc-deficient SOD1 was the one species 
found in higher concentrations in G93A SOD1 spinal cord. The concentration was on average 0.6-0.8 μM in G93A spinal cord, compared to 0.1-0.3 μM zinc-
deficient  SOD1  found  in  the  wild-type  mouse  spinal  cord.  A  concentration 
above  0.5  μM  zinc-deficient  SOD1  was  sufficient  to  induce  motor  neuron 
death  in  vitro.  These  results  suggest  that  copper-containing,  zinc-deficient 
SOD1 could be the toxic species responsible for motor neuron death in ALS. 
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Introduction and Thesis Overview 
   2 
 
1.1 Amyotrophic Lateral Sclerosis 
 
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative 
disorder  characterized  by  tremors,  muscle  weakness,  and  muscle  wasting 
leading to general paralysis and death [1]. It is better known in the United 
States as Lou  Gehrig’s disease, after the Yankees first baseman who  was 
stricken  with  the  disease  during  the  latter  part  of  his  playing  career.  Lou 
Gehrig  is  still  considered  to  be  the  greatest  first  baseman  to  ever  play 
baseball, and one of the most prolific hitters of his generation [2]. However, in 
1938 at the age of 35, he complained of being tired by mid-season, and by 
1939, he could barely run around the bases [3]. He retired from baseball that 
season and was referred to the Mayo clinic, where he was diagnosed with 
ALS. He died two years later, just shy of 38 years old [3]. Despite more than 
70 years passing since, there is still no effective treatment for the disease. 
ALS is a disease of motor neurons, the cells in the body responsible for 
controlling  muscle  movement  [4].  Motor  neurons  serve  as  the  mediator  of 
signals between the brain and the muscles and fall into two broad categories: 
upper motor neurons and lower motor neurons. Upper motor neurons originate 
in the brain motor cortex or the brain stem and carry signals down the spinal 
cord to lower motor neurons, but do not directly enervate the muscles. Lower 
motor neurons are found in the ventral horn of the spinal cord and pass out 
axons up to a meter in length to enervate and control muscles. ALS is due to 
the progressive death of both upper and lower motor neurons, leading to an 
inability to control voluntary muscle movement [5]. The disease is uniformly 
fatal, and patients typically die within 2-5 years, usually from respiratory failure 
due  to  an  inability  to  control  the  diaphragm  [6].  Jean-Martin  Charcot,  a 
preeminent  French  neurologist,  is  generally  credited  with  the  first  detailed 
description of the disease in 1874 [7]. He painstakingly laid out the symptoms 3 
 
and  correlated  them  with  anatomical  observations  at  autopsy,  arriving  at  a 
remarkably complete clinical picture of the disease:  
 
“I  do  not  think  that  elsewhere  in  medicine,  in  pulmonary  or 
cardiac  pathology,  greater  precision  can  be  achieved.  The 
diagnosis  as  well  as  the  anatomy  and  physiology  of  the 
condition  ‘amyotrophic  lateral  sclerosis’  is  one  of  the  most 
completely  understood  conditions  in  the  realm  of  clinical 
neurology.” 
 
The clinical picture of the disease has changed little since this statement [8]. 
Yet while the description of the disease may have been understood, it would 
be well over 100 years before insights into a mechanism for the disease could 
be found [9]. 
ALS strikes approximately 5 out of 100,000 individuals, with most cases 
(80-90%) referred to as ‘sporadic’ ALS (sALS) because of a lack of a family 
history of the disease [6]. The remaining 10-20% of ALS cases show a genetic 
inheritance pattern and are termed ‘familial’ (fALS). These cases also lack a 
reason for symptom onset other than a family history of the disease. It was not 
until 1993 that the first gene linked to ALS was identified. In 1991, Siddique et 
al. described localizing a genetic defect linked to the disease in 23 families to 
the long arm of chromosome 21 [10]. Two years later, Rosen et al. identified 
the gene locus as superoxide dismutase 1 (SOD1) and revealed 11 different 
point mutations associated with the disease [11]. The mutations account for 
approximately 3-6% of all ALS cases (20% of fALS and 1-2% of sALS) and for 
the first time provided a distinct molecular target for researching the disease 
[12,13].  
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1.2 Superoxide Dismutase 1 
 
The  fact  that  single  amino  acid  changes  to  SOD1  can  lead  to  ALS 
highlights the need to understand the structure of the protein and how it might 
be altered by mutation. SOD1 is a 32-kD, homodimeric antioxidant enzyme 
primarily  responsible  for  scavenging  superoxide  radicals  in  the  cell.  Each 
subunit binds a copper and a zinc ion that are essential to its function. The 
bulk  of  the  polypeptide  is  folded  into  an  8-stranded  Greek-key  β-barrel 
structure (Figure 1.1) [14,15]. 
Two loops also form significant parts of the structure of the enzyme: 
Loop  IV,  also  called  the  zinc-binding  loop,  and  Loop  VI,  also  called  the 
electrostatic loop. Three histidines (H46, H48, H120) from the β-barrel and 
one  from  Loop  IV  (H63)  comprise  the  copper  binding  site,  situated  on  the 
front-middle area of the β-barrel. The histidine from Loop IV is also a ligand for 
the  adjacent  zinc  ion,  with  two  additional  histidines  (H71,  H80)  and  an 
aspartate (D83) comprising the rest of the four zinc binding ligands.  
Zinc is a key structural feature, acting as one of the pins for Loop IV, 
which  forms  much  of  the  dimer  interface.  A  second  pin,  in  the  form  of  an 
intrasubunit  disulfide  bond  between  C46  (Loop  IV)  and  C157  (β-barrel), 
tethers the other end of the loop to the main structure of the protein. This 
disulfide linkage is unusual due to the fact that the protein maintains the bond 
in the oxidized state even in the highly reducing environment of the cytosol. 
The  unique  structural  features  of  SOD1  convey  an  extremely  high  level  of 
stability to the protein. SOD1 remains active even in 10 M urea, and has a 
melting temperature above 70 °C [16,17]. 
The copper ion is the central part of the active site of the protein. It is 
mostly occluded from solvent by Loop VI, which sits over the top of the metal-
binding region, with the exception of a small channel, the mouth of which is 
guarded by the positively charged arginine 143. Such an arrangement seems 5 
 
to increase the efficiency of the enzyme, as the positively-charged arginine 
can electrostatically guide superoxide anions to the copper [18]. Mutation of 
the arginine to amino acids other than lysine causes at least a 10-fold drop in 
protein  activity  [19].  The  normal  activity  consists  of  the  copper  ion  cycling 
between the +2 and +1 oxidation states to dismutate superoxide radicals into 
oxygen and hydrogen peroxide:  
( )       
                      
( )      
                              
The enzyme is one of the most efficient known, with a rate constant of 2-3x10
9 
M
-1s
-1 for both reactions [20].  
  Interruption of the normal activity of SOD1 as a result of mutation was 
an early hypothesis for the cause of ALS; however toxicity as a result of the 
loss of SOD1 activity was discounted due to several pieces of evidence. First, 
many ALS-causing mutant proteins, including G93A, retain the same level of 
activity as the wild-type protein [21]. Second, an SOD1 knockout mouse was 
developed that failed to show any symptoms of the disease over its normal 
lifespan [22]. Finally, a mouse model of ALS was developed in which mutant 
SOD1  was  grossly  overexpressed,    leading  to  a  recapitulation  of  many 
features  of  the  human  disease  [23].  The  overall  dismutation  activity  in  the 
mouse model animals is approximately 4-fold higher than in non-transgenic 
mice. Mutations to SOD1 clearly cause it to gain an aberrant, toxic property 
that is responsible for the disease presentation. The creation of the animal 
model enables the toxic gain-of-function to be studied in detail. 
 
1.3 Transgenic Animal Model 
 
In 1994, Gurney et al. found that overexpression of mutant SOD1 in a 
mouse yielded an ALS model that recapitulated many features of the human 
disease [23]. Expression of SOD1 with a glycine mutated to alanine at position 6 
 
93  caused  mice  to  develop  motor  neuron  pathology,  ataxia  and  muscle 
wasting,  leading  to  paralysis  and  death.  The  transgene  used  to  make  this 
mouse was a 12.1-kb fragment of genomic DNA containing the entire SOD1 
gene, including the native upstream region and promoter [24]. This resulted in 
the  incorporation  of  variable  copy  numbers  of  the  gene  into  the  mouse 
genome. A key point is that higher gene copy number was correlated with 
more  aggressive  disease  progression.  In  the  most  aggressive  line,  B6SJL-
Tg(SOD1-G93A)1Gur/J, symptoms start at around 100-110 days of age and 
are terminal by 120-130 days of age. This line carries around 25 copies of the 
G93A human SOD1 gene [25]. The control animals for these mice are B6SJL-
Tg(SOD1)2Gur/J, which were made in a similar fashion but overexpress the 
wild-type  SOD1  protein.  These  animals  display  no  characteristic  ALS 
symptoms and live a normal lifespan. However, the wild-type SOD1 animals 
only carry about 7 copies of the gene and the mRNA levels are about half that 
of the G93A mice [23]. 
The  SOD1  overexpressing  mice  are  some  of  the  most  successful 
models  of  neurodegenerative  disease  [26].  Many  of  the  SOD1  mutants 
expressed in mice result in at least some of the classic disease symptoms 
[27,28],  providing  a  wealth  of  knowledge  about  the  disease  progression. 
Several key modifiers of the disease, out of the many that have been studied, 
have dramatic effects on the onset and progression. The copper chaperone for 
SOD1 (CCS) has been of great interest because it is responsible for conferring 
the copper ion that is central to SOD1 activity to the protein [29]. G93A mice 
that have been bred to have the endogenous mouse CCS knocked out (CCS 
null  G93A)  show  no  differences  in  disease  onset  or  progression,  despite 
radioactive 
64Cu incorporation experiments that demonstrated lower copper-
loading [30]. The authors drew the conclusion that the copper cofactor could 
not play a role in the disease despite the fact that the SOD1 retained almost 
20%  of  normal  activity.  Furthermore,  the  tissues  were  homogenized  in  1% 7 
 
detergent  with  1  mM  metal  chelator  present,  suggesting  that  the 
measurements may represent a significant underestimate of the copper bound 
to  the protein  [31].  CCS  overexpression  in  the  context  of  the  G93A  SOD1 
mouse  line  has  almost  the  opposite  effect  of  the  knockout  [32].  Mice 
overexpressing both G93A and CCS die 80% faster from ALS symptoms than 
those that have just the G93A SOD1 transgene alone, consistent with copper 
toxicity  having  a  role  in  the  disease.  However,  the  precise  effect  of  CCS 
overexpression on the metals bound to SOD1 is not known. 
Small-molecule antioxidants such as glutathione may also play a role in 
the disease. The knock out of  the modulatory subunit of γ-glutamylcysteine 
ligase (GCLM) in concert with G93A SOD1-overexpression produces animals 
that  die from  ALS  50%  faster  than  the  G93A  transgene  by  itself  [33]. The 
knockout of GCLM leads to glutathione levels that are 80% lower than wild-
type animals, suggesting that glutathione may play a protective role, which has 
been  demonstrated  in  cell  culture  [34].  Induction  of  Nrf2,  an  activator  of 
glutathione synthesis, is also protective [35]. Glutathione is a potent reducing 
agent and is capable of reducing the disulfide bond of SOD1, but is also an 
excellent copper chelator and may impact the metal-binding of SOD1 [36].  
Clearly  the  various  mouse  models  provide  an  excellent  source  of 
information about the progression of ALS. The role that SOD1 plays in the 
disease progression, however, is still nebulous. Exactly how do single-amino 
acid changes to a  16-kDa protein lead to a neurodegenerative phenotype? 
Almost two decades of research since the discovery of mutations to SOD1 
have not revealed a clear answer. Linking all of the mutations to a common 
disease mechanism has been exceedingly difficult due to the diversity of the 
mutations to SOD1 that have been linked to ALS. At the most recent count, 
there are 165 mutations that lead to the development of disease (Figure 1.2) 
[37].  8 
 
These mutations can occur in all five exons and are therefore spread 
along a wide array of environments in the structure of the protein. Most of the 
mutations are dominantly inherited, single amino acid substitutions. However, 
the  D90A  mutation  is  recessive  in  some  populations  [38,39],  and  several 
truncation  and  insertion  mutations  have  also  been  described  [38].  These 
features have made a common toxic characteristic difficult to discern.  
Several hypotheses concerning the toxic function have been proposed. 
Much of the research has focused on the level of destabilization imparted to 
the protein by mutation. SOD1 is a highly stable enzyme that has an unfolding 
half-life of 70 days at 37 °C [40]. However, mutations lessen that stability to 
varying degrees and in many cases the level of destabilization imparted by the 
mutation correlates with the pace of disease progression [41]. This has led to 
the  hypothesis  that  destabilization  leading  to  aggregation  of  the  protein  is 
responsible  for  the  toxicity  of  the  mutant  protein  [42].  The  aggregates  are 
insoluble proteinaceous inclusions that can be observed both in the human 
disease and in the mouse model [43,44]. These aggregates are presumed to 
be toxic by interfering with the proteasome, sequestering other crucial cellular 
components, or perhaps disrupting axonal transport [45,46]. Direct toxicity of 
aggregates has been difficult to demonstrate, however, and it is not clear that 
propensity to aggregate can fully explain the toxicity of mutant SOD1 [47,48]. 
Many  of  the  lower  expressing  SOD1  ALS  models  demonstrate  little  to  no 
aggregation.  Indeed,  SOD1  aggregates  may  simply  be  a  symptom  of  the 
disease [49,50]. 
 
1.4 Copper, Zinc, and SOD1 
 
  Although destabilization of the protein leading to aggregation may not 
explain the toxicity of mutant SOD1, the stability of the protein may be related 
to  the  disease  in  another  fashion.  The  presence  of  soluble  yet  partially-9 
 
unfolded forms of SOD1 in mouse models has increasingly been documented, 
along  with  biophysical  folding  studies  of  the  protein  suggesting  that  such 
species represent stable intermediates in the unfolding pathway [51,52]. Much 
of the research has focused on the intermediate states of the apo protein as 
the precursor of aggregate species serving as the toxic molecule [53]. Often 
overlooked is the fact that the metal ion cofactors are intrinsically involved in 
the  folding,  stability,  and  function  of  the  protein  [54,55].  Alterations  to  the 
normal metal-binding of the protein can dramatically change how SOD1 folds, 
interacts  with  chaperones,  and  how  effectively  it  scavenges  superoxide 
[56,57]. The copper ion in particular is capable of oxidative chemistry beyond 
scavenging of superoxide. For instance, it can carry out the back reaction that 
results in the production of superoxide instead of the dismutation:  
( )                          
    
Superoxide by itself is a relatively weak reductant and not highly toxic [58]; 
however, superoxide has another fate that may play a role in ALS progression. 
The radical-radical recombination of superoxide with nitric oxide produces the 
peroxynitrite anion, a highly toxic species [59]. Nitric oxide is capable of out-
competing SOD1 for reaction with superoxide, with a rate constant of 1x10
10 
M
-1s
-1 for the formation of peroxynitrite [60].  
( )             
           
Peroxynitrite  is  a  potent  oxidant  that  can  lead  to  protein  nitration  in  vivo 
[61,62].  Such  nitration  can  fundamentally  alter  the  function  of  the  protein, 
leading  to  cellular  damage  and  death  [63-65].  Motor  neurons  in  particular 
seem to be sensitive to this, as trophic factor withdrawal leads to motor neuron 
death via peroxynitrite [66,67]. 
  Alvaro Estévez has begun to describe a more specific consequence of 
peroxynitrite:  the  downstream  toxicity  of  the  nitration  of  a  single  protein, 
HSP90.  In  an  attempt  to determine  if nitrotyrosine  played  an  active  role  in 
peroxynitrite-mediated cell death, PC12 cells were treated with peroxynitrite 10 
 
and the homogenates subjected to mass spectrometry analysis to identify any 
nitrated targets. HSP90 treated with peroxynitrite and delivered back to cells 
was  able  to  initiate  a  Fas-dependent  cellular  death  cascade.  Nitration  at 
tyrosine 33 or 56, but not mutation to phenylalanine, was sufficient to initiate 
the cascade even if present on only 1% of the HSP90. Using an antibody to 
nitrated  HSP90  revealed  intense  staining  in  motor  neurons  of  ALS-model 
mice, suggesting this pathway may be relevant for ALS. 
How  might  SOD1  participate  in  peroxynitrite-mediated  toxicity?  The 
loss of zinc from SOD1 yields a protein that binds only copper. Blaine Roberts, 
a former member of the Beckman lab, and colleagues showed that zinc loss 
opens up of parts of the protein  [68], more readily enabling  the chemistry 
described  by  reaction  (3).    Furthermore,  zinc-deficient  SOD1  is  actually 
capable  of  catalyzing  protein  nitration  [57].  Zinc-deficient  SOD1  has  been 
shown  to  be  toxic  to  motor  neurons  in  cell  culture  through  a  peroxynitrite-
mediated  mechanism  involving  tyrosine  nitration  [69-71].  The  zinc-deficient 
protein was toxic regardless of whether or not it contained an ALS-associated 
mutation; that is, even wild-type SOD1 can be toxic if it loses its zinc ion. The 
structural zinc ion is bound significantly less tightly than the copper cofactor 
and  mutant  SOD1s  are  susceptible  to  losing  zinc  [55,57,72].  However,  a 
number  of  groups  have  found  evidence  that  zinc-deficient  SOD1,  and  by 
extension  the  idea  of  copper-mediated  toxicity,  is  not  relevant  to  disease 
progression. The previously mentioned CCS null G93A SOD1 mice were used 
as  evidence  that  CCS-dependent  copper-loading  had  no  impact  on  the 
disease  progression,  thus  suggesting  copper  was  not  playing  a  role  in  the 
disease [30]. The high levels of metal chelators used in that study, however, 
suggest that the experiments were not accurate measures of either copper or 
zinc bound to SOD1 [31]. 
Further evidence cited against the zinc-deficient SOD1 hypothesis was 
the generation of a transgenic mouse expressing SOD1 with mutations to the 11 
 
four  copper-liganding  histidines  (H46R,  H48Q,  H63G,  H120G),  yielding  a 
protein  (Quad  SOD1)  that  has  diminished  capacity  to  bind  copper  [73].  
Although  the  mouse  does  demonstrate  an  ALS-like  phenotype,  copper  is 
known to be capable of binding to the zinc site, and the metal-binding of the 
Quad  SOD1  in  vivo  is  not  known  [74].  Wang  et  al.  measured  copper 
incorporation of the Quad protein using radioactive 
64Cu, and demonstrated no 
copper incorporation into the protein. However, as with the CCS null G93A 
mice,  high  levels  of  detergent  (2%  SDS,  0.5%  Nonidet  P40)  were  used  in 
preparation  for  gel  electrophoresis,  likely  impacting  the  degree  of  metal 
binding to the protein. Recently, Prudencio et al. generated a SOD1 protein 
that lacks all metal-binding and free cysteine residues, and mice expressing 
this SOD1 do not develop disease [75]. The authors suggest this is because a 
lack  of  cysteines  at  positions  6  and  111  confers  a  dramatically  lowered 
propensity to aggregate relative to other ALS mutants that have those thiols 
present. Nevertheless, the lack of both primary and secondary metal binding 
sites leading to a protein that does not lead to disease symptoms is strongly 
suggestive of the involvement of metal-binding in pathology. 
The perturbations of SOD1 mouse models used to argue against the 
potential role of zinc-deficient SOD1 in ALS, the knowledge that zinc-deficient 
SOD1  is toxic to  motor neurons  in  cell  culture  via  a  peroxynitrite-mediated 
mechanism,  and  the  elucidation  of  a  downstream  pathway  tying  nitrated 
HSP90  to  cell  death  all  highlight  a  knowledge  gap  in  determining  if  this 
represents the pathway of ALS progression: is zinc-deficient SOD1 present in 
a disease relevant context? The SOD1 metal-binding in vivo is not known for 
the Quad SOD1, the CCS null G93A, the normal G93A SOD1, or even the 
wild-type  SOD1  mice.  Indirect  measures  of  metal-binding,  such  as  activity 
assays, are used as evidence for the amount of copper binding, but they do 
not provide an accurate picture of how the metal is distributed at the subunit-
level,  information  that  is  crucial  for  determining  if  aberrantly  metal-bound 12 
 
populations  of  SOD1  are  involved  in  ALS.  Addressing  this  question  and 
determining the metal-binding of SOD1 in disease-relevant tissue throughout 
the progression of disease in an animal model has been the primary goal of 
my dissertation.  
 
1.5 Contents of the Dissertation 
 
The remainder of my dissertation is comprised of 4 chapters focused on 
the development of methods to look at the metal-binding distribution of SOD1 
throughout the course of ALS in disease model-animals. Chapters 2-4 are full 
research  articles,  of  which  Chapter  2  is  published,  and  Chapter  3  will  be 
submitted in the near future. Chapter 5 draws together the  insights gained 
from the research, places the work in the context of the field, and describes 
the possibilities for future research. 
 
Chapter 2: “Measuring copper and zinc superoxide dismutase from spinal cord 
tissue using electrospray mass spectrometry” Timothy W. Rhoads, Nathan I. 
Lopez,  Daniel  R.  Zollinger,  Jeffrey  T.  Morré,  Brian  L.  Arbogast, Claudia  S. 
Maier,  Linda  DeNoyer,  Joseph  S.  Beckman.  Analytical  Biochemistry,  2011, 
415 (1), 52-58. 
   
This  manuscript  presents  the  development  of  a  mass  spectrometry-
based assay to measure SOD1 from the spinal cords of transgenic rats and 
mice. Utilizing a C4 Ziptip® and a custom interface to a time-of-flight mass 
spectrometer, we were able to detect human SOD1 from 200 μg or less of 
regiospecific areas of transgenic rat spinal cord tissue. We demonstrated that 
electrospray ionization conditions could be made sufficiently gentle to keep 
native  metals  bound,  and  that  three  distinct  metal-binding  populations  of 
SOD1  were  observed:  apo  (no-metals),  one-metal,  and  two-metals  bound. 13 
 
This  represented  the  first  look  at  the  specific  metal  binding  distribution  of 
SOD1  in  ALS-affected  tissue.  However,  the  resolution  of  the  time-of-flight 
mass  spectrometer  used  for  the  study  was  not  sufficient  to  distinguish 
between copper- and zinc-bound SOD1, necessitating further work. 
 
Chapter  3:  “Theoretical  protein  isotopic  distributions  as  a  means  to  parse 
small-mass-difference  post-translational  interactions  via  mass  spectrometry” 
Timothy W. Rhoads, Jared R. Williams, Nathan I. Lopez,  Jeffrey T. Morré, 
Joseph S. Beckman. Manuscript submitted to Journal of the American Society 
for Mass Spectrometry. 
 
Due to the small mass difference between zinc and copper, we needed 
some additional tools to be able to distinguish between the two in the context 
of SOD1 from transgenic spinal cord tissue. We present in this chapter the 
transfer  of  our  Ziptip  methodology  to  a  Fourier  transform  ion  cyclotron 
resonance  mass  spectrometer,  an  instrument  capable  of  acquiring  high 
resolution mass data. For an intact protein, the mass peak was resolved into 
individual isotopic species. This data required improvements to our methods of 
data analysis. As such, we developed a suite of custom-written programs to fit 
combinations  of  theoretical  isotope  distributions  to  the  experimental 
distributions, arriving at a best-fit that represents the relative proportions of 
each metal. We also developed a simple and rapid assay for assessing the 
oxidation  status  of  the  disulfide  bond,  setting  the  stage  for  being  able  to 
measure the metal-distribution of SOD1 in a larger number of animals. 
 
Chapter  4:  “Assessing  the  impact  of  metal-binding  and  disulfide  status  of 
superoxide dismutase on amyotrophic lateral sclerosis” Timothy W. Rhoads, 
Jared  R.  Williams,  Nathan  I.  Lopez,  Joseph  S.  Beckman.  Manuscript  in 
preparation. 14 
 
 
This chapter presents a larger scale examination of the metal-binding of 
SOD1 in tissues from ALS model mice and controls (G93A and wild-type). We 
assessed the metal-binding of SOD1 in the spinal cords and brains of 40 mice 
of  varying  ages  and  disease  progression,  finding  that  wild-type  SOD1 
overexpressing  mice  contained  more  of  all  forms  of  partially-unfolded 
intermediates  of  SOD1  except  for  copper-containing,  zinc-deficient  SOD1, 
which was higher in G93A mice. We discovered that a small molecule present 
in  the  spinal cords  of  these  animals prevented us from measuring  copper-
containing, zinc-deficient SOD1 unless we included the thiol-oxidant diamide 
in the tissue buffer. The necessity of diamide to measure zinc-deficient SOD1 
suggests other molecules that may be involved in the disease, which will be 
addressed in Chapter 5. We found that with the inclusion of diamide, we could 
measure 800 nM zinc-deficient SOD1 in the spinal cords of G93A transgenic 
mice  and  that  the  level  in  wild-type  SOD1  mice  was  200  nM,  significantly 
lower. Experiments performed by Alvaro Estévez’s lab indicated that the level 
in G93A animals is enough to be toxic while that in wild-type animals is below 
the toxic threshold. 
Chapter 5 describes the conclusions that can be drawn from the work 
and the direction of the research going forward. We have developed a method 
that allows us to look closely at SOD from relevant tissue in a simple, rapid 
manner  and  have  our  first  look  at  the  specific  metal-binding  status  of  the 
protein  as  the  disease  progresses.  These  studies  set  the  stage  for further 
research into the role that metal-binding plays in ALS. 
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Figure 1.1 Superoxide Dismutase 1 dimer. Superoxide dismutase 1 cartoon 
depiction (pdb code 2c9v). Features of the protein highlighted: Copper (burnt 
orange), zinc (grey), metal ligands (green), Loop IV (blue), disulfide bond 
(yellow), Loop VI (orange), Arg143 (pink). 
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Figure  1.2  ALS-linked  Mutations  to  SOD1.  Human  Cu,Zn  superoxide 
dismutase  (Pdb  code  2c9v)  with  the  ALS-causing  mutations  highlighted  in 
blue. The list of mutations is available at http://alsod.iop.kcl.ac.uk/. 17 
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Measuring copper and zinc superoxide dismutase from spinal cord 
tissue using electrospray mass spectrometry 
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2.1 Abstract 
 
Metals are key cofactors for many proteins, yet quantifying the metals 
bound  to  specific  proteins  is  a  persistent  challenge  in  vivo.  We  have 
developed a rapid and sensitive method using electrospray ionization mass 
spectrometry to measure Cu,Zn superoxide dismutase (SOD1) directly from 
the  spinal  cord  of  SOD1-overexpressing  transgenic  rats.  Metal 
dyshomeostasis has been implicated in motor neuron death in amyotrophic 
lateral sclerosis (ALS). Using the assay, SOD1 was directly measured from 
100  g  of  spinal  cord,  allowing  for  anatomical  quantitation  of  apo,  metal-
deficient, and holo SOD1.  SOD1 was bound on a C4 ZipTip® that served as a 
disposable  column,  removing  interference  by  physiological  salts  and  lipids. 
SOD1 was eluted with 30% acetonitrile, plus 100 M formic acid to provide 
sufficient hydrogen ions to ionize the protein without dislodging metals. SOD1 
was quantified by including bovine SOD1 as an internal standard. SOD1 could 
be measured in subpicomole amounts and resolved to within two Daltons of 
the  predicted  parent  mass.  The  methods  can  be  adapted  to  quantify 
modifications  to  other  proteins  in  vivo  that  can  be  resolved  by  mass 
spectrometry. 
   19 
 
2.2 Introduction 
 
Approximately one-third of all proteins are predicted to require a metal 
cofactor for activity [76] and as many as half of all the structures deposited in 
the Protein Data Bank contain a metal ion [77]. Metal ion binding to proteins is 
critically important for many biological processes [78], but characterizing the 
metal ions bound to a protein in a biological context is difficult. Spectroscopic 
techniques, such as atomic absorption, electron paramagnetic resonance, and 
Mössbauer  reveal  metal  coordination  by  proteins,  but  are  insensitive  and 
require purified protein in high concentrations [79]. Inductively-coupled plasma 
mass spectrometry and assays utilizing colorimetric chelators inform on the 
total  metal  content  in  the  sample,  thus  conveying  only  average  metal  ion 
stoichiometry [80,81]. Electrospray ionization mass spectrometry (ESI-MS) is a 
well-established technique used in the study of non-covalent modifications and 
interactions  of  proteins  such  as  metal  binding  [82-85].  Once  the  ionization 
parameters are properly optimized, metal ions such as zinc and copper remain 
tightly associated with proteins during electrospray ionization and ESI-MS has 
been used to compare both relative and absolute metal ion affinities of many 
proteins [86,87].  
The activity of Cu,Zn superoxide dismutase (SOD1) is vitally dependent 
upon its copper and zinc cofactors [88]. The redox-active copper is the center 
of  the  protein’s  activity.  SOD1  also  contains  a  structural  zinc  atom  closely 
coordinated to the copper that is essential for the proper folding of the protein 
[55].  Evaluating  the  metals  bound  to  SOD1  is  also  important  because 
mutations to the protein cause a toxic-gain-of-function that is responsible for 2-
7% of all cases of amyotrophic lateral sclerosis (ALS) [9,12]. ALS is a fatal 
neurodegenerative disorder characterized by the progressive death of motor 
neurons.  However,  the  mechanism  of  the  toxic  function  in  vivo  is  still 
controversial. Most of the mutant SOD1 proteins bind one copper and one zinc 20 
 
ion per subunit and many retain almost the same level of enzymatic activity as 
the wild-type protein [89-91]. However, the mutant SOD1 proteins seem to be 
more susceptible to the loss of the zinc ion than the wild-type SOD1 protein in 
vitro [57,92,93]. We have previously shown that purified zinc-deficient SOD1 
delivered to cultured motor neurons is toxic [94]. Furthermore, expression of 
mutant SOD1 in motor neurons isolated from SOD1-transgenic animals kills by 
the same mechanism [95]. Consequently, the ability to assess the amounts of 
copper and zinc bound to SOD1 in the specific spinal cord regions affected by 
ALS may provide clues as to the nature of the toxic function in vivo. 
Here we introduce a sensitive ESI-MS based method that allows the 
quantification  of  SOD1  directly  from  spinal  cord  tissue  of  transgenic  ALS-
model rats and concurrently reports on the zinc and copper ion content of the 
protein. We demonstrate the efficacy of the method for SOD1 from transgenic 
spinal  cord  tissue,  although  it  can  be  applied  to  other  proteins  in  complex 
mixtures. 
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2.3 Materials and Methods 
 
2.3.1 Reagents and Equipment 
Lyophilized bovine SOD1 (EC1.15.1.1, Sigma-Aldrich, St. Louis, MO, 
USA) was  rehydrated  with  Milli-Q  water (reverse-osmosis system),  and  the 
concentration  was  determined  spectrophotometrically  at  259  nm  (=  5150     
M
-1cm
-1 for the Cu,Zn containing monomer) [88]. 
Two types of human SOD1 were used in the development of this assay. 
The  first  type  was  recombinant  SOD1  expressed  in  Escherichia  coli 
(recombinant  SOD1) with  coexpression  of  the  copper chaperone  for SOD1 
(CCS).  The  protein  was  purified  as  described  in  Hayward  et  al.  [96]. 
Ammonium  sulfate  was  used  in  high  concentrations  for  hydrophobic 
interaction  chromatography,  causing  a  sulfate  adduct  (+98  Da)  to  be  often 
present  in  mass  spectrometry  samples.  The  concentration  was  determined 
spectrophotometrically at 265 nm (= 9200 M
-1cm
-1 for the Cu,Zn containing 
monomer)  [88].  Recombinant  SOD1  was  found  to  have  the  amino-terminal 
methionine cleaved and was not acetylated [97]. The second type was SOD1 
from  tissue  samples  of  mutant  G93A  SOD1-overexpressing  transgenic  rats 
(referred to as tissue SOD1). These rats develop fatal motor neuron disease 
and die around 120 days old [98]. In eukaryotic sources, SOD1 is acetylated 
on the amino-terminus, increasing the protein mass by 42.1 Da. 
The  solvent  used  for  the  mass  spectrometric  experiments  was  30% 
acetonitrile, 70% water and 100 M formic acid, delivered at a flow rate of 30 
L/min from a single isocratic pump (Shimadzu, Kyoto, Japan). The solvent 
was  degassed  for  10  minutes  with  helium  and  was  changed  each  week. 
HPLC-grade  solvents  were  used  for  all  mass  spectrometer  experiments. 
Water was obtained from Burdick and Jackson (Muskegon, MI, USA) and 10% 
formic acid from Michrom Bioresources (Auburn, CA, USA). Universal grade 
acetonitrile was obtained from VWR (West Chester, PA, USA).  22 
 
SOD1  was  introduced  into  the  mass  spectrometer  via  one  of  two 
methods: by direct injection of SOD1 in low ionic strength aqueous buffers, or 
by binding to a C4 reversed phase Ziptip® for tissue samples or higher ionic 
strength  solutions  as  described  below.  For  direct  injection,  solvent  was 
pumped from the HPLC pump through PEEK® tubing with an interior diameter 
of 0.005 inches to a 2-way, 6-port Rheodyne injection port. The SOD1 was 
introduced into the sample loop of the injector via a 50 L Hamilton syringe 
with a blunt tip. Solvent was then pumped through the loop and across a 1 m 
inline stainless steel microfilter (Upchurch Scientific, Oak Harbor, WA, USA) to 
prevent clogging. The 0.005 inch inner diameter PEEK® tubing led from the 
microfilter into the mass spectrometer inlet. 
 
2.3.2 Ziptip Method 
A C4 Ziptip (Millipore, Billerica, MA, USA) was used as a disposable 
desalting column while binding SOD1. The Ziptip is a P10 pipette tip with 0.6 
L of reversed phase C4 packing material that is typically used to remove salts 
from peptide samples in preparation for mass spectrometry detection. For the 
assay,  a  Ziptip  was  prepared  by  rinsing  three  times  (10  L  each)  with 
acetonitrile,  followed  by  four  washes  with  water.  The  washes  were 
accomplished by using a P10 pipette to repeatedly draw 10 µL of fresh solvent 
up through the Ziptip, and then to expel the solvent. The SOD1 sample was 
then bound to the Ziptip by pipetting the protein solution three times, followed 
by rinsing six times with water to remove salts. The Ziptip was then inserted 
between the injection port and the microfilter (Figure 2.1). 
 
2.3.3 Tissue Measurements 
Fresh  spinal  cord  tissues  from  transgenic  G93A-SOD1
+/- 
overexpressing rats housed in Institutional Animal Care and Use Committee-
approved facilities were extracted via dissection of euthanized animals and 23 
 
frozen at -80 C until use. The tissue was too brittle to section immediately at 
this temperature, and was placed on an insulating plastic plate on top of dry 
ice and allowed to warm to approximately -20 C. Punches were taken from 1 
mm  thick  transverse  sections  of  tissue  using  a  500  micron  biopsy  punch 
(Figure 2.1). An air-filled syringe was attached to the rear of the punch to expel 
the  tissue  (Zivic  Instruments,  Pittsburgh,  PA,  USA).  The  punches  were 
weighed on a Cahn 25 Automatic Electrobalance with a sensitivity of 0.1 g 
(Cerritos, CA, USA). SOD1 was released from the tissue punch by thawing the 
tissue in 5 L of 10 mM ammonium acetate, adjusted with acetic acid to pH 
5.1, that included 200 nM bovine SOD1 (punch thawing buffer). The pH was 
chosen  to  reduce  adventitious  metal  binding  and  because  interfering 
lipoproteins  from  central  nervous  system  tissues  precipitated,  thereby 
preventing  clogging  of  the  tubing  [99].  The  thawed  tissue  was  vortexed  at 
maximum speed for 30 seconds then centrifuged for two minutes at 16,000 rcf. 
The supernatant was  adsorbed onto the Ziptip, eluted and analyzed in the 
mass spectrometer. 
The amount of SOD1 released from tissue was verified by western blot 
analysis.  The  supernatants  from  three  punches  were  combined  to  provide 
enough sample per lane for the western blot. The punches were thawed in 15 
L  of  10  mM  ammonium  acetate  at  pH  5.1,  vortexed  and  centrifuged  as 
above. The tissue supernatant and pellet fractions were separated, the volume 
of each was adjusted to 30 L with Laemmli buffer [100], and the samples 
were heated for five min at 95 C.  Samples were then run on a 10% SDS-
PAGE at 150V for 60 min in a Bio-Rad Mini Protean II system. Gels were 
transferred  to  a  polyvinylidene  fluoride  membrane  (Bio-Rad  product  #  162-
0177)  for  60  min  at  100V.  SOD1  was  detected  using  rabbit  polyclonal 
antibodies raised in the laboratory against human SOD1 (1:10,000). Affinity-
purified antibodies retained cross reactivity with mouse and rat SOD1. The 24 
 
secondary  antibody  was  goat  anti-rabbit  IgG  heavy  plus  light  chain-horse 
radish peroxidase conjugate (Bio-Rad #170-6515). 
 
2.3.4 Data Analysis 
Proteins  were  detected  using  a  LCT  Premier  Time-of-Flight  mass 
spectrometer (Waters, Milford, MA, USA) with an electrospray ionization (ESI) 
interface in positive ion mode with capillary and sample cone voltages set to 
3000 and 60 V, respectively. Nitrogen was used as a desolvation gas (400 
L/hr), with a desolvation temperature of 120 C. The scan range was set from 
820 to 2450 m/z, which allowed for all SOD1 peaks to be recorded.  
Data  were  collected  using  MassLynx  software  (Waters,  v.  4.1)  and 
mass  spectrum  deconvolution  and  integration  was  performed  using  the 
program MOP
TM (Multiple Overlaying Pictures, Spectrum Square Associates, 
Inc.) described below. Custom code written in Matlab
TM (The MathWorks, Inc., 
Natick, MA, USA) was used to transfer the data from MassLynx to MOP
TM and 
perform the peak integration. Deconvolution of electrospray m/z data to yield 
the  zero  charge  parent  mass  spectrum  was  accomplished  with  the 
Bayesian/maximum  entropy  algorithm  MOP
TM.  The  program  makes  no 
assumptions about the types of proteins present in the spectrum. The only 
information provided to the program is 1) that hydrogen ions are the source of 
charge,  and  2)  the  resolution  of  the  mass  spectrometer.  The  program 
assumes  that  noise  is  distributed  according  to  a  Poisson  distribution  and 
incorporates a mass-dependent point-spread function for a time-of-flight mass 
analyzer to account for instrumental blurring. The program uses an algorithm 
based  on  Bayes  theorem  to  calculate  the  most  probable  parent  mass 
distribution that would result in the observed multiply charged experimental 
spectrum with experimental noise. It incorporates a multinomial Bayesian prior 
and thus becomes the standard maximum entropy approach. The algorithm 
preserves the observed number of ion counts in the original spectrum and thus 25 
 
the output peak areas remain proportional to the concentration of the species 
present. SOD1 concentrations were determined by the use of bovine SOD1 as 
an internal standard. A comparison of the total integration of the human SOD1 
peaks with the integration of the bovine SOD1 peak at a known concentration 
generated a ratio that allowed us to determine the human SOD1 concentration 
in the original solution. Bovine SOD1 was chosen because it behaves similarly 
to  human  SOD1  and  binds  the  same  metals,  and  therefore  serves  as  an 
internal protein control in addition to a standard. 
Molecular weights and theoretical isotope distributions were calculated 
from  the  empirical  formula  of  SOD1  using  the  program  iMass  [101,102]. 
Identical  results  were  obtained  using  the  isotopicdist  function  in  the 
Bioinformatics Toolbox of Matlab
TM. To account for the two positive charges of 
each of the copper and zinc ions, two hydrogen atoms were subtracted for 
each metal ion bound so that SOD1 remained electrically neutral. In addition, 
two hydrogen atoms were subtracted for the internal disulfide bond in SOD1.  
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2.4 Results 
 
Copper and zinc remained associated with SOD1 during electrospray 
ionization  in  a  aqueous  solution  containing  100  µM  formic  acid  and  30% 
acetonitrile  as  shown  by  the  mass  spectrum  of  recombinant  SOD1  ALS-
mutant G93A (Figure 2.2A). Recombinant SOD1 protein was used to develop 
the assay before using tissue samples. The mass spectrometer displayed six 
prominent peaks corresponding to the 13
th through 8
th charge states, with the 
most  intense  being  the  10
th-12
th  charge  states.  Deconvolution  using  the 
Bayesian  maximum-entropy  method  generated  the  parent  mass  spectrum 
(Figure 2.2B). The main peak was centered at 15941 Da, which agreed well 
with  the  average  mass  of  15941.7  calculated  for  the  Cu,Zn  G93A  SOD1 
monomer (C680H1081N203O224S4CuZn). The width of the observed SOD1 peak 
corresponds to the broadening predicted from the natural isotope distribution 
using the empirical formula for Cu,Zn G93A SOD1 (Figure 2.2C).  
Physiological  concentrations  of  sodium  chloride  caused  the  mass 
spectrum  to  be  unrecognizable  as  recombinant  SOD1  and  could  not  be 
deconvoluted (Figure 2.3A). A Ziptip used as a rapid and disposable desalting 
column reversed the effects of the salt (Figure 2.3B). The Ziptip contained C4 
reverse-phase packing material upon which the SOD1 could be adsorbed and 
rinsed with water to remove salts. An internal standard of bovine SOD1 was 
included in each sample to quantify the levels of SOD1 and control for any 
sample loss. Bovine SOD1 is shorter by two amino acids than human SOD1 
and thus is well resolved from the three potential metal ion-containing forms of 
human  SOD1.  The  charge  state  distribution  for  Cu,Zn  G93A  SOD1  in  the 
presence of high salt could be deconvoluted after use of the Ziptip to give a 
mass of 15941 Da, identical to the spectrum of SOD1 with no salt present.  
The  chromatogram from  a  sample  of  bovine  and  recombinant G93A 
SOD1  showed  that  less  than  three  minutes  was  needed  for  SOD1  to 27 
 
isocratically elute from the Ziptip into the mass spectrometer (Figure  2.4A). 
The concentration of acetonitrile in the running solvent (30%) was optimized to 
be  at  the  lowest  level  possible  while  still  rapidly  releasing  SOD1  from  the 
Ziptip. Dilute formic acid (100 µM) included in the running solvent substantially 
improved ionization of the protein. Although acidic conditions are known to 
cause  metal  ion  release  from  SOD1,  the  formic  acid  concentration  was 
optimized  to  provide  sufficient  hydrogen  ions  for  ionization  while  allowing 
copper  and  zinc  to  remain  stably  bound  to  SOD1  [16].  Metal  ions  were 
retained under the acid conditions over the period necessary to acquire the 
data, as shown by the deconvoluted mass spectrum of recombinant SOD1 
incubated in water versus running solvent (30% acetonitrile/water with 100 µM 
formic acid) for 5 minutes at room temperature (Figure 2.4B,C). Without the 
rinse step that accompanies the use of a Ziptip, the sulfate adduct peak 98 
mass  units  higher  than  the  mass  of  the  recombinant  SOD1  monomer  was 
more prominent. 
Tissue G93A SOD1 could easily be picked out from the other abundant 
background proteins as it was significantly overexpressed in the spinal cord of 
G93A-SOD1 overexpressing transgenic rats (Figure 2.5A). The SOD1 could 
be quantified by use of the Ziptip and the inclusion of bovine SOD1 as an 
internal standard. To generate a standard curve, bovine SOD1 was kept at 
800 nM, while the concentration of recombinant G93A SOD1 was varied over 
a range of 200 nM-1.2 µM (Figure 2.5D). The relationship was linear over the 
concentration  range  tested  with  a  slope  of  approximately  1.3  (R
2=0.995). 
Representative spectra from the dorsal and ventral (Figure 2.5B) grey matter 
of  the  spinal  cord  of  an  ALS-model  rat  showed  three  distinct  metal-bound 
species: a Cu,Zn SOD1 peak, a one-metal SOD1 peak, and a small apoSOD1 
peak.  The  one-metal  peak  was  approximately  2-fold  larger  in  the  disease-
affected ventral spinal cord as compared to that from the dorsal spinal cord. 
Thawing of frozen tissue punches was sufficient to release SOD1 and other 28 
 
soluble proteins from the punch into solution; this was verified via  Western 
blots that showed less than 2% of SOD1 in the remaining pellet compared to 
the supernatant fraction (Figure 2.5C).  
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2.5 Discussion 
 
Analysis  of  proteins  in  complex  mixtures  on  a  Ziptip  via  mass 
spectrometry  provides  a  rapid,  quantitative  means  to  assay  noncovalent 
modifications  directly  from  tissues  that  is  comparable  and  possibly  more 
sensitive  than  western  blotting.  The  remarkable  sensitivity  of  the  method 
allows  for  anatomical  microdissection  of  the  tissue.  ALS  affects  motor 
neurons, which are localized in the ventral spinal cord (Figure 2.1). This assay 
allows SOD1 to be directly measured from the disease-affected regions, and is 
able to distinguish between one-, two-, and no-metal bound states; the one-
metal  bound  species  is  significantly  larger  in  the  ventral  compared  to  the 
dorsal spinal cord. This difference is lost if the entire spinal cord is used, as 
several previous methods have done [50,103,104]. 
Three main issues needed to be addressed in developing the assay. 
The first was to maintain metal binding to the protein while providing sufficient 
acidity to permit efficient electrospray ionization [105,106]. We found that 0.1% 
formic acid, commonly used in ESI-MS coupled liquid chromatography, was 
too  strong  and  could  cause  SOD1  to  lose  metals  during  the  assay  [16]. 
Hayward et al, used 0.1% formic acid to look at apo mutant SOD1 proteins 
[96]. Leaving out formic acid resulted in poor ionization because the solvent 
could not provide enough hydrogen ions in solution to effectively ionize SOD1. 
The largest amounts of human Cu,Zn SOD1 eluting from the Ziptip were in the 
range  of  1-10  pmol  in  a  volume  of  a  few  microliters,  resulting  in  a 
concentration  of  1-10  M.  Because  the  charge  states  of  SOD1  typically 
ranged from 8 to 13, the concentration of hydrogen ions needed to be 8-13 M 
(Figure 2.2A). We found that solvent containing 100 M formic acid delivered 
at a flow rate of 30 L/min provided enough protons for efficient ionization. 
The 100 M formic acid concentration is approximately 200-fold more dilute 
than the standard 0.1% concentration, and was able to efficiently ionize SOD1 30 
 
without altering metal binding after five minutes, twice the time needed to run 
the assay (Figure 2.4B,C). 
The second issue to overcome was how to efficiently remove salts from 
the protein solution that would otherwise interfere with electrospray ionization. 
Salts suppress ionization of proteins, interfering with the deconvolution of raw 
m/z data (Figure 2.3A). Sodium ions in particular can associate strongly with 
an ionizing protein and sodium chloride is approximately 100 mM in the central 
nervous  system,  thereby  presenting  a  significant  potential  interference  to 
ionizing  proteins  directly  from  tissue.  We  used  a  C4  Ziptip  to  desalt  the 
samples.  The  Ziptip  is  a  P10  pipette  tip  with  a  small  amount  of  HPLC 
reversed-phase  packing  material.  As  tissue  lysate  is drawn  over  it,  soluble 
proteins  bind  to  the  packing  material.  Once  bound,  the  proteins  could  be 
rinsed multiple times with water, washing off salts and other small hydrophilic 
molecules while leaving the proteins bound to the packing material. The bound 
proteins  could  be  eluted  in  the  mass  spectrometer  with  the  minimal 
concentration of acetonitrile needed to elute SOD1 (30%) (Figure 2.4A). 
The third issue was to quantify the amount of human SOD1 released 
from  the  tissue.  This  was  accomplished  by  including  an  internal  standard, 
bovine  SOD1,  at  a  known  concentration  in  the  punch  thawing  buffer. 
Comparing the integration of the peak areas from MOP
TM of the bovine and 
human  SOD1  allowed  us  to  calculate  the  amount  of  human  SOD1  in  the 
punch  supernatant,  which  could  be  used  to  estimate  the  concentration  of 
human SOD1 in the tissue. SOD1 was found to be 16 pmol/mg tissue in the 
dorsal spinal cord and 26 pmol/mg tissue in the ventral spinal cord. These 
amounts  roughly  translate  to  16  and  26  M  in  the  cells,  respectively.  A 
standard curve of recombinant human SOD1 compared to bovine SOD1 was 
used to determine if the ionization of the human and bovine proteins differed 
(Figure 2.5D). The slope of 1.3 on the standard curve suggests that human 
SOD1 may ionize more efficiently than bovine SOD1 due to the higher number 31 
 
of basic amino acid residues present in the human SOD1 sequence. This can 
also be seen in the differing charge state distributions of human and bovine 
SOD1, in which the human protein picks up two more positive charges on 
average than bovine SOD1 (Figure 2.3B). 
One of the primary advantages of our method is the ability to monitor 
the  metal-binding  of  SOD1  at  the  monomer  level  in  complex  mixtures,  in 
contrast  to  other  approaches  that  can  determine  the  metal-binding  of  the 
population  of  SOD1  as  a  whole  solution,  thus  giving  only  average 
stoichiometry [104]. This is an important distinction in being able to determine 
if metal-deficient SOD1 species are involved in ALS. An SOD1 dimer has 9 
different metal-binding combinations distinguishable by mass. The intrasubunit 
disulfide  bond  further  complicates  matters,  as  it  can  be  in  an  oxidized  or 
reduced  state,  altering  the  mass  of  the  protein  by  two  Da.  Indeed  several 
groups have reported that as much as 20-30% of the SOD1 in the ALS model 
animals is reduced [107]. Combining these two phenomena, the SOD1 dimer 
has 27 distinct combinations of metal-binding and disulfide states, which would 
yield a complex and hard-to-interpret spectrum. An advantage of the described 
method  is  that  the  dimer  dissociates  in  the  course  of  the  assay  and  only 
monomer  is  detected  (Figure  2.2B).  The  SOD1  monomer  has  only  eight 
distinct  metal-binding/disulfide  states,  with  the  resulting  spectrum  being 
significantly easier to interpret, facilitating analysis of the metal-binding status 
of individual subunit populations. 
A second advantage is that the method is highly adaptable, allowing 
monitoring  of  other  proteins  and  post-translational  modifications.  We  have 
used the method to measure recombinant proteins in solution such as CCS, 
hemoglobin, and di-iron mono-oxygenases. Other proteins were also observed 
when measuring SOD1 from tissue, such as ubiquitin and acyl-CoA-binding 
protein  which  were  tentatively  identified  by  their  mass  (Figure  2.5A).  The 
endogenous  rat  SOD1  was  also  identified,  although  in  a  significantly  lower 32 
 
amount  that  the  human  SOD1  (Figure  2.5B).  Taking  advantage  of  other 
materials available for ZipTips (C18, etc.) could further extend the method to 
additional  proteins.  Modifying  the  solvent  composition  and  the  ionization 
parameters, such as the ionization voltage and capillary temperature, allows 
the  method  to  be  optimized  for  other  proteins  and  post-translational 
modifications, possibly including small-molecule binding, nitration, metals, and 
phosphorylation.  Furthermore,  these  modifications  can  be  monitored  in  a 
dynamic fashion, as both modified and unmodified populations of a protein are 
observed at the same time.  
The main limitation to our assay is the inability to distinguish between 
copper-containing, zinc-deficient SOD1 and zinc-containing, copper deficient 
SOD1.  The  isotopically  broad  mass  spectrometer  signature  of  a  protein  is 
wider than the mass difference between zinc and copper, and thus we cannot 
differentiate  between  the  two  (Figure  2.2C).  However,  we  find  a  significant 
one-metal SOD1 peak that is substantially larger in the ventral gray matter, 
which  provides  additional  evidence  that  non-natively  metal-bound  SOD1 
species are involved in the progression of the disease (Figure 2.5B). Further 
work that is now ongoing will be needed to determine the composition of the 
one metal peak and elucidate whether either species has a role in the disease. 
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  ESI-MS,  electrospray  ionization  mass  spectrometry;  SOD1,  Cu,Zn 
superoxide  dismutase;  ALS,  amyotrophic  lateral  sclerosis;  CCS,  copper 
chaperone for superoxide dismutase; MOP, multiple overlaying pictures.   35 
 
 
Figure 2.1 Tissue preparation for Ziptip® assay with mass spectrometer 
interface. A 500 micron biopsy punch is taken from a 1 mm spinal cord slice, 
thawed in buffer and adsorbed onto a  Ziptip. Solvent from an HPLC pump 
flowed  through  0.005  inch  interior diameter  PEEK  tubing  that  was  inserted 
snugly into the back of the Ziptip. The end of the Ziptip was inserted into a 
second short segment of PEEK tubing with an interior diameter of 0.03 inches 
that had been slightly expanded with a dissecting needle to fit the end of the 
Ziptip snuggly. A stainless steel 1  m microfilter was inserted between the 
Ziptip and the mass spectrometer inlet to trap large particulates released from 
the Ziptip. 
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Figure 2.2 Mass spectra of G93A SOD1. A. The Ziptip m/z spectrum of 1 μM 
G93A  SOD1  in  10  mM  ammonium  acetate,  showing  the  charge  state 
distribution of  the  protein,  with  the  10th-12th  charge  states  being  the most 
prominent.  B.  Mathematical  deconvolution  of  the  m/z  spectrum  yields  the 
parent mass spectrum, showing a singular peak centered at a mass of 15941. 
*The spectrum also contained a small peak centered at 16039 (observable in 
A as well). This peak, which is 98 mass units larger than Cu,Zn G93A SOD1, 
likely  corresponding  to  a  sulfate  (H2SO4)  adduct  remaining  from  the 
purification process. C. Overlay of the experimental mass spectrum with the 
theoretical  high  resolution  mass  spectrum  calculated  from  the  empirical 
formula  for  G93A  SOD1  with  the  program  iMass.  The  high  resolution 
theoretical spectrum  is used to  illustrate  the  effects  of  isotopic broadening, 
primarily due to the natural isotope distribution. 
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Figure 2.3 Elimination of salt interference using a Ziptip to bind G93A 
SOD1. A. Mass spectrum of bovine and G93A SOD1 directly injected in the 
presence of 100 mM sodium chloride.  B. Mass spectrum of bovine (*) and 
G93A (^) SOD1 with 100 mM sodium chloride after washing with the Ziptip. 
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Figure 2.4 Stability of metal binding of G93A SOD1 in elution solvent. A. 
Chromatogram  of  G93A  SOD1  eluting  from  the  Ziptip.  B.  Parent  mass 
spectrum  of  G93A  SOD1  mixed  immediately  in  elution  solvent  and  directly 
injected into the mass spectrometer. C. Parent mass spectrum of G93A SOD1 
incubated in elution solvent for 5 minutes to mimic the maximum exposure of 
SOD1 to solvent when bound to a Ziptip. *In both B and C, the sulfate-bound 
SOD1 peak was more prominent probably due to the absence of the washing 
step used with the Ziptip. 
 
   39 
 
 
Figure 2.5 Metal content of G93A SOD1 in transgenic rats with symptoms 
of motor neuron degeneration. A. Deconvoluted mass spectrum of a ventral 
tissue punch from the lumbar spinal cord of a G93A SOD1-overexpressing rat 
shown  over  the  mass  range  8000  to  24000  Da.  Several  other  proteins, 
including ubiquitin, ubiquitin minus two glycine residues (-114 Da), and acyl-
CoA binding protein were observable in addition to SOD1. B. Overlay of the 
mass spectra of dorsal and ventral tissue punches from the lumbar spinal cord 
of a G93A SOD1 overexpressing rat. Prominent peaks are identified in the 
spectrum,  including  the  endogenous  rat  SOD1.  C.  Western  blot  of  tissue 
punch supernatant (S) and pellet (P) fractions used to verify the release of 
SOD1  into  the  supernatant.  The  SOD1  standards  were  4,  2,  and  1  pmol, 
respectively. D. Standard curve using bovine SOD1 as an internal standard at 
a concentration of 800 nM and varying the G93A SOD1 over a concentration 
range of 200 nM-1.2 M. The ratio of the peak integrations of the G93A SOD1 
over the bovine SOD1 was plotted against the amount of G93A SOD1 in the 
sample to produce the standard curve.   40 
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3.1 Abstract 
 
Small-mass-difference modifications to proteins are obscured in mass 
spectrometry by the natural abundance of stable isotopes such as 
13C that 
broaden the isotopic distribution of an intact protein when observed by mass 
spectrometry. Using a Ziptip to remove salt from proteins in preparation for 
high  resolution  mass  spectrometry,  the  theoretical  isotopic  distribution 
intensities  calculated  from  the  protein’s  empirical  formula  could  be  fit  to 
experimentally acquired data and used to differentiate between multiple low-
mass modifications to proteins. We could distinguish copper from zinc bound  
to a single-metal superoxide dismutase (SOD1) species; copper and zinc only 
differ by an average mass of 1.8 and have overlapping stable isotope patterns. 
In addition, proteins could be directly modified while bound to the Ziptip. For 
example,  washing  10  mM  S-methyl  methanethiosulfonate  over  the  Ziptip 
allowed the number of free cysteines on proteins to be detected as S-methyl 
adducts. Alternatively, washing with 10 mM diamide could quickly reestablish 
disulfide  bridges.    Using  these  methods,  we  could  resolve  the  relative 
contributions of copper and zinc binding, as well as disulfide reduction to intact 
SOD1 protein present from <100 μg of the lumbar spinal cord of a transgenic, 
SOD1 overexpressing mouse. Although techniques like ICP-MS have provided 
solution  metal  amounts,  this  is  the  first  method  able  to  assess  the  metal-
binding and sulfhydryl reduction of SOD1 at the individual subunit level and is 
applicable to many other proteins. 
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3.2 Introduction 
 
Many  mass  spectrometers  in  principle  have  sufficient  resolution  to 
distinguish 1-2 Da mass differences in intact proteins that result from small 
post-translational  modifications  such  as  disulfide  bond  formation  [108]. 
However, the natural abundance of 
13C and other stable isotopes in proteins 
obscures such low mass modifications because the same number of protein 
ions  are  distributed  over  dozens  of  isotopic  mass  peaks  [109,110].  The 
intensities of the isotopic peaks can be predicted from the empirical formula of 
a protein with sufficient accuracy to distinguish even the addition of a single 
hydrogen  atom  [101,102,110].  Experimentally  obtained  intensities  therefore 
contain a significant amount of information regarding the empirical formula of 
the molecule in question. Senko et al. used an experimental distribution based 
on  a  model  amino  acid,  averagine,  to  assign  the  monoisotopic  peak  and 
empirical formula of myoglobin [110]. However, while the averagine method 
they used can calculate a distribution that closely matches the experimentally 
acquired  data,  the  determined  empirical  formula  did  not  match  the  correct 
formula exactly. Assigning the oxidation status of a metal ion, a single dalton 
mass change, has also been accomplished using isotopic distributions [111]. 
In this case, however, the authors looked at distributions that contained only 
one species. Green et al. distinguished between two species differing by 1 Da 
by identifying the tallest peak via the calculation of a centroid of the isotopic 
distribution over 50% of the maximum height [112]. This limits the ability to 
differentiate  between  differences  in  low  abundance  species  that  may 
contribute to less than 50% of the isotopic distribution, as could be the case 
when measuring proteins from in vivo samples. The challenge then is whether 
or not the isotopic distributions of proteins could be used to quantify multiple, 
simultaneous modifications to proteins isolated from tissue. 43 
 
Our interest stems from the need to measure the metal content of the 
antioxidant  protein  copper,  zinc  superoxide  dismutase  (SOD1),  a  protein 
genetically linked to amyotrophic lateral sclerosis (ALS), from in vivo samples. 
We have previously shown that a C4-reversed phase Ziptip® could be used to 
measure  SOD1  from  less  than  100  g  of  spinal  cord  from  transgenic  rats 
[113]. The Ziptip allowed salts and other contaminants that would otherwise 
interfere with mass spectrometry to be removed by washing with water. After 
washing, the Ziptip was mounted directly into the electrospray interface of a 
Time-of-Flight (ToF) mass spectrometer and proteins were eluted with a small 
amount of acetonitrile.  
Although  conditions  for  electrospray  ionization  could  be  made 
sufficiently gentle with the Ziptip method to keep metals bound to SOD1, a 
majority of the protein isolated from the spinal cord of transgenic animals was 
missing one metal. The missing metal from SOD1 in these tissues could be 
either copper or zinc, whose average masses differ by only 1.8 Daltons. Our 
method using ToF mass spectrometry lacks the resolution to distinguish such 
overlapping species. Determining whether the remaining metal was copper or 
zinc  in  vivo  is  important  because  we  have  previously  shown  that  copper-
containing, zinc-deficient SOD1 is toxic to motor neurons  [94], but have no 
means of assaying zinc-deficient SOD1 from transgenic animal model tissue. 
The  measurement  of  zinc-deficient  SOD1  is  further  complicated 
because  the  protein  has  an  unusually  stable  intrasubunit  disulfide  bond 
restraining  the  zinc-binding  loop.  Additionally,  the  disulfide  is  known  to  be 
partially reduced in transgenic SOD1 overexpressing animals [103,107,114-
117].  The  extent  of  disulfide  reduction  in  vivo  is  controversial  because  of 
differences in measurement methods between laboratories.  
No method has been able to simultaneously determine which metals 
remain bound to disulfide-reduced versus oxidized SOD1 subunits in vivo. To 
address  these  issues,  we  adapted  the  Ziptip-based  assay  for  use  with  a 44 
 
Fourier  transform  ion  cyclotron  resonance  (FT-ICR)  mass  spectrometer  to 
accurately  measure  the  isotopic intensity  distributions  of  intact  proteins.  By 
comparing  the  predicted  isotope  distribution  calculated  from  the  empirical 
formula to the experimental high-resolution mass spectrum, it is possible to 
distinguish the contributions that each metal ion makes to the experimental 
isotopic  distribution  of  SOD1.  Reduction  of  the  disulfide  bond  was 
independently  assessed  by  modifying  reduced  cysteines  with  S-methyl 
methanethiosulfonate (MMTS). The combination of these methods could also 
be  useful  for  probing  multiple  modifications  to  other  proteins  in  addition  to 
SOD1.   45 
 
3.3 Materials and Methods 
 
3.3.1 Reagents and Equipment 
All  chemicals  were  obtained  from  VWR,  unless  otherwise  noted. 
Chicken lysozyme, bovine ubiquitin, and MMTS were obtained from Sigma-
Aldrich.  Bovine  SOD1  from  erythrocytes  was  obtained  from  Sigma.  Its 
concentration was determined spectrophotometrically at 258 nm (= 5150 M
-
1cm
-1  for  the  Cu,Zn  containing  monomer).  Wild  type  and  pseudo-wild  type 
C111S human SOD1 expressed in Escherichia coli (recombinant SOD1) with 
coexpression  of  the  copper  chaperone  for  SOD1  (CCS)  were  used  for 
developing many of the assays. C111S SOD1 is more stable than wild-type 
human SOD1 and was used here to verify the rapid modification of a single 
thiol  was  due  to  C111.  The  SOD1  protein  was  purified  as  described  in 
Hayward  et  al  [96],  and  the  concentration  was  determined 
spectrophotometrically at 265 nm (= 9200 M
-1cm
-1 for the Cu,Zn containing 
monomer) [88]. Recombinant forms of human SOD were not acetylated on the 
N-terminus.  
To generate copper- or zinc-containing single metal SOD1 standards, 
both metals were stripped from Cu,Zn SOD1 by incubating the protein (>1 
mg/mL)  in  50  mM  acetate  pH  3.7  with  1.5  mM  EDTA.    Once  metal-free, 
copper-containing SOD1 was prepared by multiple additions of 15 µM copper 
nitrate  atomic  absorption  standard  (Sigma-Aldrich),  in  10  mM  potassium 
acetate at pH 4.15 with 10 mM sodium chloride, to the SOD1 in an Amicon 
Ultra 0.5 mL centrifugal filter with a 3k MWCO. This was centrifuged for 10 
minutes at 16,000 rcf after each addition. Zinc-containing SOD1 was prepared 
in a similar manner through multiple additions of 15 µM zinc chloride atomic 
absorption standard (Sigma-Aldrich), in 10 mM potassium acetate at pH 4.6 
with 10 mM sodium chloride.  The number of metal additions was determined 
by  monitoring  metal  incorporation  into  SOD  after  each  addition  via  mass 46 
 
spectrometry. All buffer solutions and water were run through a Chelex 100 
(50-100 dry mesh, Sigma) column prior to use. 
The  solvent  used  for  the  mass  spectrometric  experiments  was  30% 
acetonitrile, 70% water and 100  M formic acid, delivered isocratically at a 
flow  rate  of  20  L/min from a  single pump  (Shimadzu,  Kyoto,  Japan). The 
solvent  was  degassed  for  10  minutes  with  helium  and  was  changed  each 
week. HPLC-grade solvents were used for all mass spectrometer experiments. 
Water was obtained from Burdick and Jackson (Muskegon, MI, USA).  
 
3.3.2 Ziptip Method 
SOD1  was  also  measured  from  tissue  samples  of  wild-type  SOD1-
overexpressing  transgenic  mice  (B6SJL-Tg(SOD1)2Gur/J).  In  eukaryotic 
sources,  SOD1  is acetylated  on  the  amino-terminus,  increasing  the  protein 
mass  by  42.1  Da.  All  animal  procedures  and  housing  arrangements  were 
approved  by  IACUC  (institutional  animal  care  and  use  committee).  Fresh 
spinal cord tissues from transgenic wild-type-SOD1 mice were extracted via 
dissection  of  euthanized  animals  and  frozen  at  -80  C  until  use.  Frozen 
necropsy punches taken from 1 mm thick spinal cord slices were thawed in 10 
mM ammonium acetate, pH 5.1, via centrifugation. The buffer, containing the 
soluble proteins, was adsorbed onto a C4 reversed-phase Ziptip® (Millipore, 
Billerica,  MA,  USA),  and  then  introduced  into  the  mass  spectrometer  as 
described previously [113].  
Probing the oxidation status of free cysteines was done using either 
MMTS or diamide. Diamide is a thiol oxidant, and could be used to ensure all 
disulfide  bonds  were  oxidized  [118].  This  served  as  a  negative  control  for 
using MMTS to determine if a disulfide bond was oxidized or reduced. MMTS 
modifies  accessible  free  thiols  with  a  methylthiol  group.  In  developing  the 
MMTS assay, lysozyme pre-incubated with 100 μM TCEP was used. Proteins 
were first adsorbed onto the Ziptip as above, but before rinsing with water the 47 
 
tip was rinsed once with 10 μL of 10.6 mM MMTS. The short (<5 seconds) 
exposure time was sufficient to modify all free thiols on the protein of interest. 
 
3.3.3 
13C Measurements 
  The ratio of 
13C incorporated into a protein can vary depending on the 
source of carbon in either the bacterial media or in the mouse diet, which in 
turn reflects differences in carbon fixation between C3 and C4 plants [119].  
Stable isotope analysis of tissues and purchased proteins was carried out by 
the Stable Isotope Research Unit (SIRU), Department of Crop and Soil 
Sciences, Oregon State University. Samples were analyzed for total carbon 
and 
13C on a PDZ Europa 20-20 isotope ratio mass spectrometer interfaced 
with a SerCon GSL elemental analyzer (SerCon, Crewe, UK). To determine % 
carbon, dry sample material was weighed to the nearest microgram on a Cahn 
microbalance prior to combustion. Liquid samples were pipetted onto an inert 
sorbant material (Chromosorb, SerCon, Crewe, UK). Samples were packaged 
in pressed tin capsules (Elemental Microanalysis, Devon, UK).  The 
laboratory-working standard was NIST SRM1547 peach leaves (45.54% C, δ 
13C VPDB -25.99). To correct for possible drift in the EA/IRMS combination 
with time, drift correction standards of equal mass were run every 10 samples. 
Additional standards were run as after every 10 samples. Stable isotope ratios 
were reported in delta notation as parts per thousand deviation from the 
international standard V-PDB. Typical precision for the SIRU 20-20 IRMS was 
<0.2 parts per thousand deviation for 
13C. These values were incorporated into 
the theoretical protein isotopic distribution calculations.  
 
3.3.4 Mass Spectrometry 
 Proteins were detected using a LTQ-FT Ultra hybrid linear ion trap-
Fourier transform ion cyclotron resonance mass spectrometer (Thermo, San 
Jose, CA) with a Finnigan
TM Ion Max
TM API source configured for electrospray 48 
 
ionization (ESI) interface in positive ion mode. Measurements to determine the 
specific metals bound to the protein were accomplished in the ICR cell at a 
chosen resolution of 100,000 defined at 400 m/z, while quantitation of total 
protein levels using bovine SOD1 as an internal standard was performed in 
the linear ion trap.  
Spectra  were  collected  using  Tune-Plus  (Thermo,  v.  2.2)  page  of 
Xcalibur (Thermo, v. 2.0.5) using the parameters given in Table 1. Spectra 
were averaged over the 3 minutes of the elution of SOD1 from the Ziptip using 
the  Qual  Browser  (Thermo,  v.  2.0).  The  data  were  exported  as  text  files 
containing  two  columns  of  m/z  versus  intensity  to  be  analyzed  by  custom 
programs  written  in  MatLab
TM.  The  baseline  was  subtracted  and  centroids 
calculated  from  the  experimental  data  using  programs  provided  in  the 
Bioinformatics Toolbox of MatLab. The parent mass distribution of SOD was 
reconstructed by summing the spectral regions containing individual charge 
states  of  SOD  multiplied  by  their  charge  after  subtracting  the  number  of 
hydrogen  atoms  corresponding  to  the  charge  state  [120].  Bayesian 
deconvolution of the mass/charge spectra as previously used with our ToF 
measurements was not necessary due to the clarity and high signal/noise ratio 
of the data. 
 
3.3.5 Matlab Programming and Data Analysis 
Intensities of theoretical isotopic distributions were calculated for apo, 
copper-containing,  zinc-containing  and  Cu,Zn  SOD1  via  the  Rockwood 
algorithm [102] using only the empirical formulas of the particular SOD mutant 
protein under investigation and the experimentally determined 
13C/
12C ratios 
(Table  3.2). The  theoretical isotopic distributions  calculated for SOD1  were 
calculated  for  electrically  neutral  parent  molecules,  so  a  hydrogen  ion  was 
removed for each  charge  carried  by  the metal ions bound  to SOD1.   Two 
hydrogen  atoms  were  subtracted  for  the  reduction  of  the  intra-molecular 49 
 
disulfide  bond  between  C57  and  C146.  The  theoretical  spectra  also  were 
calculated with multiple additions when SOD was treated with the sulfhydryl-
modifying agent MMTS.  
Fitting of experimental to theoretical data was done in two steps.  The 
predicted  m/z  centroids  from  the  theoretical  isotopic  spectra  were  first 
matched to the closest m/z values for experimental centroid peaks for each 
charge state of SOD1 in the experimental spectra.  The Levenberg-Marquardt 
fitting  algorithm  was  then  used  to  determine  the  optimal  scaling  of  the 
normalized intensities of theoretical spectra with overlapping distributions to 
match experimentally measured centroid data. The fit was constrained to allow 
only  positive  intensities.  Predicted  isotope  intensities  less  than  1%  were 
ignored  in  the  fitting  program.  The  scaling  factors  were  summed  over  all 
observable  charge  states  to  determine  the  relative  contribution  of  each 
species to the overall observed spectrum.  
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3.4 Results 
 
3.4.1 Optimization of Mass Spectrometry Parameters 
As illustrated with lysozyme, the Ziptip interface worked well with the 
FT-ICR for many  small  proteins,  enabling  collection of  isotopically  resolved 
spectra that could then be combined into a parent mass spectrum (Figure 3.1). 
The isotopic intensities predicted from the empirical formula of lysozyme with 
four  disulfide  bonds  accurately  fit  to  the  experimentally  acquired  isotope 
distribution (Figure 3.2), so long as the number of ions filling in the FT cell was 
kept below an empirically determined limit. Increasing the ion fill beyond this 
level distorted the isotopic distribution as seen with ubiquitin (Figure 3.3A-C). 
At lower ion fill levels, sensitivity decreased and the decreased signal to noise 
resulted  in  worse  fitting  to  the  predicted  spectra.  Consequently,  the  ion  fill 
needed to be experimentally optimized for each type of protein, with smaller 
proteins generally fitting better with lower ion fills. 
Copper-deficient  and  zinc-deficient  SOD1  standards  were  used  to 
validate the fitting program’s ability to differentiate between copper and zinc in 
a one-metal peak (Figure 3.4-3.6). C111S SOD1 prepared with only zinc fit as 
exclusively  zinc-containing  SOD1  (Figure  3.4).  C111S SOD1 prepared  with 
only  copper  fit  as  mostly  copper-containing  SOD1  with  6%  of  the  peak 
corresponding to zinc-containing SOD1 (Figure 3.5). These two single-metal 
standards,  when  combined  in  equimolar  amounts,  produced  an  isotopic 
distribution  that  was  fit  containing  48%  copper-containing  and  52%  zinc-
containing  (Figure  3.6).  Copper  can  also  be  reduced  by  one  electron,  a 
phenomenon  often  observed  for  iron-containing  heme  proteins  in  the  gas 
phase. As a result, the fit required the inclusion of a second species for the 
CuZn  protein  one  mass  unit  heavier  as  a  result  of  the  additional  proton 
compensating for the loss of a charge on the copper [121]. The amount of 
copper reduction observed varied among the samples. 51 
 
3.4.2 Sulfhydryl Oxidation Status Determination with MMTS 
The intramolecular disulfide bond of SOD1 could be either reduced or 
oxidized,  shifting  the  isotopic  distribution  by  two  Daltons.  Although  the 
difference  could  be  parsed  by  the  fitting  program,  the  presence  of  other 
potentially  overlapping  species,  such  as  zinc  vs.  copper,  or  Cu
1+  vs.  Cu
2+, 
confounded the fit. For measurements of those species from tissue samples, 
we included the thiol oxidant diamide in the buffer. Diamide rapidly oxidized 
disulfide bonds, thereby preventing any overlap within the isotopic distribution 
with  the  zinc  or  copper  measurements.  Diamide  was  not  necessary  with 
recombinant protein samples as the disulfide bonds were fully oxidized.  
A  separate  assay  was  developed  to  determine  the  level  of  reduced 
disulfide present. After testing many sulfhydryl modifying reagents, we found 
that MMTS was particularly well suited to modify free thiols of proteins bound 
on the Ziptip.  Each MMTS added 47.1 Da to every free thiol within seconds of 
exposure. The reduced disulfide bond increased a protein mass by 94.2 Da 
relative  to  those  with  an  oxidized  disulfide  bond,  allowing  disulfide-reduced 
proteins to be clearly resolved from those with intact disulfide bridges. 
 Using tris(2-carboxyethyl)phosphine as a reductant, MMTS was utilized 
to determine the number of disulfide bonds of lysozyme that had been reduced 
over  a  given  period  of  time  (Figure  3.7).  Lysozyme  contains  four  disulfide 
bonds and does not bind metals like SOD1, making it a convenient molecule 
for perturbing disulfide bond status and validating MMTS for use as a free-thiol 
probe. A 100 mM concentration of tris(2-carboxyethyl)phosphine was sufficient 
to fully reduce one disulfide bond and partially reduce a second (Figure 3.7B), 
leading to a majority of the protein modified by 2 MMTS molecules and a small 
population modified by 4. Recombinant  wild-type SOD1, when reacted with 
MMTS, was modified at one cysteine only as the disulfide bond was entirely 
oxidized, while C111S SOD1 was not modified (data not shown). 
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3.4.3 Detection of SOD1 from Tissue 
Human  SOD1  could  be  observed  above  the  background  soluble 
proteins of a 100 g punch of SOD1-overexpressing mouse spinal cord, as 
had previously been observed in transgenic rats [113]. Surprisingly, the one-
metal  SOD1  peak  comprised  almost  60%  of  total  SOD1  while  38%  of  the 
SOD1 contained both copper and zinc (Figure 3.8). Apo SOD1 represented 
less than 2% of the total SOD1. Without diamide present, the one-metal SOD1 
peak  showed  a  systematic  shift  to  a  slightly  higher  mass  relative  to  the 
predicted  isotopic  distribution,  indicating  the  existence  of  a  population 
containing a reduced disulfide bond. MMTS modification revealed 15% of the 
one-metal SOD1 contained a reduced disulfide bond, closely matching the fit 
of  13%.  In  the  presence  of  diamide,  the  shift  to  higher  mass  was  absent, 
indicating oxidation of the disulfide bond. The one-metal peak fits entirely as 
zinc-containing SOD1 with no copper present.    53 
 
3.5 Discussion 
 
The Ziptip offers a simple, fast, and reliable method to isolate proteins 
in  complex  samples  sufficiently  free  of  interference  to  allow  accurate 
measurement of the isotopic distribution. The isotopic distribution calculated 
from the empirical formula of several small proteins can match experimental 
data with a root-mean square of 1-2%, which provides sufficient accuracy to 
potentially  resolve  low  mass  post-translational  interactions  to  a  protein.    In 
addition, the proteins bound to the Ziptip can also be reacted with specific 
modifying  reagents.  For  example,  free  protein  thiols  were  modified  within 
seconds with MMTS on the Ziptip, which allowed thiol reduction to be probed 
independently  of  other  modifications.  These  methods  allowed  us  to 
simultaneously  probe  the  metal  content  as  well  as  the  reduction  of  a  key 
disulfide bridge in the same subunits of SOD1 directly from spinal cord tissues 
from transgenic mice.    
Controlling the number of ions in the FTICR proved to be important for 
accurately resolving the isotopic distribution and the ion fill needs optimization 
for  each  type  of  protein.    The  upper  limit  likely  results  from  space  charge 
repulsion between protein  ions  that affects  the  course of  the free-induction 
decay  used  to  measure  the  mass  to  charge  of  protein  ions  [122,123]. 
Overfilling of the ion cell causes the central isotopic peaks of the protein’s 
distribution  to  become  magnified,  while  the  smaller  peripheral  peaks  were 
deemphasized [124]. These deviations can be identified from a residual plot of 
deviations  (Figure  3.3A).  As  the  ion  fill  levels  were  lowered,  the  isotopic 
distributions more closely matched the theoretical distributions but the signal-
to-noise ratio eventually limited detection.    
In  developing  the  Matlab
TM  programs  to  fit  predicted  isotopic 
distributions  to  experimental  data,  we  customized  the  Rockwood  algorithm 
[101]  for  calculating  isotopic  intensity  distributions  to  allow  different 54 
 
abundances of isotopes to be included. The largest contribution to the isotopic 
distribution is the ratio of 
13C to 
12C incorporated into proteins, which can vary 
significantly in nature [119]. The major source of this variation results from 
different  photosynthetic  processes  used  to  fix  carbon  dioxide.  Due  to 
compartmentalization of different steps of carbon fixation, plants such as corn 
that use the C4 pathway discriminate against the incorporation of 
13C less than 
plants relying entirely on the C3 Calvin cycle [125]. Proteins from animals fed 
diets  enriched  in  corn  can  have  a  significantly  greater  amount  of 
13C 
incorporated, which can be observed in the spectra [126,127]. These ratios 
can  be  independently  measured  by  inductively  coupled  plasma  mass 
spectrometry and incorporated in the calculation of the predicted spectra. The 
overall effect resulted in relatively small corrections in the RMS for the fitted 
plots of up to 0.5%. Such corrections could be relevant when measuring low-
abundance species.   
The  isotopic  distributions  of  copper  and  zinc  add  considerable 
complexity to the spectrum of SOD1 and are challenging to resolve because 
copper and zinc are neighbors on the periodic chart. Yet distinguishing how 
much copper can be lost compared to zinc from SOD1 in vivo is crucial for 
understanding how this enzyme malfunctions to cause motor neuron death in 
ALS.  Tests  with  mixtures  of  metal-deficient  SOD1s  showed  that  fitting  the 
predicted isotopic distributions allows copper-containing SOD1 to be readily 
distinguished from zinc-containing SOD1.   
An  additional  potential  confounding  factor  is  the  reduction  of  copper 
from Cu
2+ to Cu
1+ that is the key event in the standard catalytic cycle of SOD1.  
Reduction of copper by one electron increases the uncharged protein mass by 
one hydrogen ion. Thus, copper reduction will increase the mass of SOD1 
containing the two stable 
63Cu and 
65Cu isotopes to equal the mass of SOD1 
containing  the 
64Zn  isotope  (48%  abundance)  or 
66Zn  isotope  (28% 
abundance).  Hence,  zinc-deficient  cuprous-containing  SOD  would  not  be 55 
 
distinguished from SODs containing the two predominant zinc isotopes and 
the  method  will  underestimate  the  amount  of  copper-containing  SOD1.  
Fortunately, this issue appears to be minor because reduction of copper in 
purified zinc-deficient SOD1 during electrospray ionization was not observed 
in  any  of  our  zinc-deficient  SOD  standards.  Experiments  with  chemically 
reduced, purified zinc-deficient SOD1 also appeared to be completely oxidized 
in the mass spectrometer. This is consistent with copper being more exposed 
in  zinc-deficient  SOD  and  able  to  be  reoxidized  during  the  electrospray 
ionization process.  
However, this does appear to be a problem for  Cu,Zn SOD1, which 
becomes partially reduced during ionization, as can be observed in Figure 3.8. 
The  observed  spectrum  for  Cu,Zn  SOD1  could  only  be  reasonably  fit  by 
assuming  a  fraction  of  the  copper  was  reduced.  The  reduction  happened 
during  the  ionization  process,  because  it  was  observed  with  both  purified 
bovine and human SOD1 that were fully oxidized. These purified SOD1s were 
confirmed to be fully oxidized before introduction into the mass spectrometer 
by measuring the cuprous d-d* band (λmax=680 nm). Reduced SOD1 has no 
absorbance at this wavelength. These fits typically found that 20-50% of Cu,Zn 
SOD1 was reduced. Chemically reduced purified Cu,Zn SOD1 also appeared 
to  be  a  mixture  of  reduced  and  oxidized  SOD.  These  results  might  be 
explained by the oxidation of formate within the steel electrospray needle to 
formate  radical  that  will  reduce  oxygen  to  superoxide.    The  superoxide 
produced  would  result  in  a  rapid  reduction  of  oxidized  SOD1  as  well  as 
oxidation  of  reduced  SOD1  to  produce  a  mixture  of  reduced  and  oxidized 
Cu,Zn SOD1 from whichever was present at the start.   
A further challenge to resolve is the potential reduction of the disulfide 
bond of SOD, which is known to occur in SOD1 transgenic mice [107]. The 
addition  of  two  hydrogens  upon  reduction  almost  perfectly  overlaps  the 
difference between copper and zinc. Parsing the difference between the two 56 
 
concurrently is not directly possible by mass measurements alone. For tissue 
measurements, we could include diamide to oxidize disulfide bonds, allowing 
us to ignore any contribution the two additional protons on a reduced disulfide 
would make to the isotopic distribution. The fitting program could easily parse 
zinc and copper bound to SOD1 in this case. However, the measurement of 
thiol reduction in SOD1 necessitated the development of another approach. 
The  majority  of  thiol  modifying  agents,  including  iodoacetamide,  iodoacetic 
acid, vinyl pyridine, and maleimides, reacted too slowly to be useful in the 
present assay.  In addition, many modifiers introduced adducts whose mass 
overlapped  with  other  metal-binding  states  of  SOD1.  MMTS,  in  contrast, 
modifies free thiol groups in less than five seconds and added a methyl thiol 
group (-SCH3; 47.1 Da). Hence, MMTS could be washed over SOD1 bound to 
the Ziptip and was simple to incorporate into the assay. Purified SOD1 bound 
one  methyl  thiol  group  immediately,  which  we  concluded  was  due  to 
modification of cysteine residue 111 since  the modification did not occur using 
the pseudo-wild type SOD1 containing the mutation of cysteine 111 to serine.  
One  caveat  with  MMTS  is  that  the  methyl  thiol  adduct  is  the  intermediate 
formation of a mixed disulfide and could exchange with another cysteine to 
reoxidize  the  disulfide  bridge  [128].  This  was  minimized  by  using  10  mM 
MMTS to modify all free thiols within seconds. 
In summary, isotopically-resolved protein mass spectrometry data offer 
a  simple  means  to  measure  non-covalent  protein  post-translational 
interactions  via  mass  spectrometry.  The  method  is  exquisitely  sensitive, 
allowing us to even measure metal contents of SOD1 from samples as small 
as  a  few  hundred  cells collected  by  laser  capture  (Figure  3.9).  It  has  also 
proved useful in assessing the correct expression and formation of disulfides 
of other recombinant proteins. The Ziptip method also allowed bound proteins 
to be probed with classical biochemical protein modifying reagents to examine 
other modifications. 57 
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3.7 Abbreviations 
 
  SOD1,  Cu,Zn  superoxide  dismutase;  ALS,  amyotrophic  lateral 
sclerosis;  ToF,  time-of-flight;  FT-ICR,  fourier  transform  ion  cyclotron 
resonance; MMTS, S-methyl methanethiosulfonate; CCS, copper chaperone 
for SOD1; IACUC, institutional animal care and use committee; SIRU, stable 
isotope research unit; ESI, electrospray ionization. 
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Table 3.1. Instrumental parameters for LTQ-FT Ultra mass spectrometer. 
ESI Source    
Sheath Gas  2 arb units 
Auxillary Gas  1 arb units 
Sweep Gas  1 arb units 
Spray Voltage  5 kV 
Capillary Temp.  200 °C 
Capillary Voltage  36 V 
Tube Lens  205 V 
Scan Parameters   
Mass Range  800-2000 m/z 
Resolution  100000 
Scan Type  Full 
Microscans  1 
Max. Inject Time  8000 ms 
ICR Cell Parameters    
Trapping Voltage  Pos 0.51 Neg -0.40 
Excite Amplitude  fm>190(+): 0.64 
  fm>98(+): 0.5 
  fm>50(+): 0.75 
Injection Control    
Full MS  8.00x10
5 ion current 
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Table 3.2. δ
13C values for proteins from different sources. 
Protein Source  δ
13C 
Recombinant  -20.24 
Bovine/Chicken  -11.94 
Rodent  -19.56 
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Figure  3.1  Charge-state  spectrum  of  chicken  lysozyme.  The  m/z 
distribution of chicken lysozyme eluted from the Ziptip, showing charge states 
9-14. 
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Figure 3.2 The parent mass spectrum of chicken lysozyme derived from 
Figure 3.1. The theoretical isotope distribution of chicken lysozyme, based on 
the  empirical  formula  C613H951N193O185S10,  was  fit  to  the  experimental 
distribution,  showing  excellent  agreement. δ
13C of  -11.94  was  used for the 
theoretical isotopic distribution calculation. 
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Figure 3.3 Effect of ion cell fill on the isotopic distribution of ubiquitin. A. 
Bovine ubiquitin was fit with the program at ICR cell AGC settings from 3x10
5 
to 5x10
6, demonstrating a systematic deviation from the expected distribution 
at ion fill levels below and above 5-7x10
5. B. Ubiquitin fit at the optimal 5x10
5 
ion fill. C. Ubiquitin fit at 3x10
6 ion fill, showing the systematic deviation. δ
13C 
of -11.94 was used for the theoretical isotopic distribution calculation. 
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Figure  3.4  C111S  SOD1  prepared  with  only  zinc.  C111S  mutant  SOD1 
single-metal standard was prepared with only zinc (green fit) as described in 
the methods. The fit was 100% zinc-containing. δ
13C of -20.24 was used for 
the theoretical isotopic distribution calculation.   65 
 
 
Figure 3.5 C111S SOD1 prepared with only copper. C111S mutant SOD1 
single-metal standard was prepared with only copper (blue fit) as described in 
the methods. A small amount of residual zinc (green fit) that varied with the 
preparation was consistently present that we were unable to remove, 6.6% in 
this  case.  δ
13C  of  -20.24  was  used  for  the  theoretical  isotopic  distribution 
calculation. 
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Figure 3.6 50-50 mixture of C111S SOD1 single-metal standards. C111S 
mutant SOD1 single-metal standard prepared with only zinc (green) or only 
copper  (blue)  were  combined  in  equimolar  amounts  and  the  resulting 
distribution fit to the theoretical isotope distributions, which returned a ratio of 
48% copper containing and 52% zinc containing SOD1. δ
13C of -20.24 was 
used for the theoretical isotopic distribution calculation. 
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Figure 3.7 Use of MMTS to determine thiol oxidation status of lysozyme. 
Lysozyme was subjected to MMTS treatment on the Ziptip as described in the 
methods  after  incubation  with  TCEP  for  0  minutes  (A)  or  30  minutes  (B), 
demonstrating the complete reduction of one disulfide bond. δ
13C of -11.94 
was used for the theoretical isotopic distribution calculation. 
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Figure  3.8  SOD1  isolated  from  the  ventral  spinal  cord  of  a  wild-type 
transgenic mouse with and without diamide. A ventral spinal cord punch 
was analyzed via the ziptip assay as described in methods. A. The one-metal  
SOD1  peak  without  diamide  shows  a  systematic  shift  towards  the  right, 
indicating the presence of some disulfide reduction. B. The same tissue run 
with  diamide  present  does  not  contain  that  shift,  indicating  the  complete 
oxidation  of  the  disulfide  bond.  The  amount  of  disulfide  reduction  was 
confirmed with our MMTS assay. δ
13C of -19.56 was used for the theoretical 
isotopic distribution calculation. 69 
 
 
 
Figure 3.9 SOD1 isolated from 400 motor neurons captured via laser 
capture microdissection. The spinal cord from a wild-type transgenic rat was 
frozen and embedded in O.C.T.
TM (Optimal Cutting Temperature) sectioning 
medium. 20 μm thick sections were cut using a cryostat and then stained with 
Cresyl violet. A. A Zeiss Laser Capture Microdissection instrument was used 
to cut and capture approximately 400 motor neurons from eight sections into 
20 μL of 10 mM ammonium acetate. A 50X magnification of one section is 
shown. Scale bar is 300 μm. B. A mass spectrum of the capture buffer was 
acquired using a Ziptip, showing Cu,Zn SOD1 from the motor neurons. 
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4.1 Abstract 
 
  The  relevance  of  the  metal-binding  of  Cu,Zn  superoxide  dismutase 
(SOD1) to mutant-SOD1-linked  amyotrophic  lateral  sclerosis  (ALS) remains 
controversial. The metals have a larger influence on the folding and stability of 
SOD1  than  any  single  mutation.  However,  they  are  frequently  ignored  in 
discussions  of  how  partially  unfolded  intermediates  of  mutant  SOD1  may 
cause ALS. We have previously demonstrated that exogenous zinc-deficient 
SOD1 is toxic to motor neurons in cell culture, but it has not been possible to 
measure  which  metal-bound  species  of  SOD1  are  present  in  vivo.  The 
development of a Ziptip-based, high resolution mass spectrometry assay to 
measure SOD1 from small amounts of spinal cord tissue while keeping metal-
binding intact now allows us to determine how the presence of zinc-deficient 
SOD1 in disease-affected tissue correlates with the progression of ALS. We 
present here a combined approach to quantify the metal-binding and disulfide 
oxidation status of SOD1 in a mouse model of ALS. This provides a detailed 
look at the partially unfolded intermediates of SOD1 present in the spinal cord 
both in pre-symptomatic, end-stage, and control SOD1 transgenic mice. We 
found  that  wild-type  SOD1  mice  contain  more  of  all  forms  of  the  partially 
unfolded  intermediate  species  of  SOD1  except  for  copper-containing,  zinc-
deficient  SOD1.  Zinc-deficient  SOD1  was  present  at  a  toxic  level  in  G93A 
mice, while the wild-type mice contained a substantially lower, likely non-lethal 
level of zinc-deficient SOD1. 
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4.2 Introduction 
 
The mechanism by which mutant forms of Cu,Zn superoxide dismutase 
(SOD1) cause amyotrophic lateral sclerosis (ALS) has remained controversial 
since the involvement of the protein in the disease was first discovered in 1993 
[9]. As of 2012, 165 different mutations to SOD1 that lead to the development 
of  the  disease  have  been  identified  (http://alsod.iop.kcl.ac.uk/).  The  rate  of 
progression of the disease can vary widely, depending on the mutation, but 
the age of onset is generally uncorrelated with any mutation [52,53]. Both the 
pattern  of  inheritance  and  experiments  with  transgenic  animals  clearly 
establish that the mutations confer a toxic gain of function rather than resulting 
in a loss of superoxide scavenging activity [23,129]. Much of the research has 
focused  on  SOD1-immunoreactive  aggregates  that  are  readily  observed  in 
animal models at the last stages of the disease. These aggregates of SOD1 
may  be  a  result  of  the  gross  overexpression  of  mutant  SOD1  in  the  most 
common  ALS  models  [43,46,130-134].  Although  these  aggregates  are 
purported  to  be  cytotoxic,  evidence  of  direct  toxicity  is  lacking.  Some  ALS 
models involving low expression of SOD1 show no evidence of aggregation 
even in terminally ill animals [50,135]. Thus aggregates of SOD1 may be a 
symptom rather than the driver of toxicity.  
The  presence  of  aggregates  in  the  disease  has  led  to  increased 
scrutiny of the mechanics of SOD1 folding and unfolding. The folding pathway 
for SOD1 includes four post-translational modifications. The first is binding of 
the zinc cofactor [136,137]. The zinc ion organizes a significant loop structure 
that contributes to the dimer interface of the protein. Once the protein has 
acquired zinc, it has enough structure to interact with the copper chaperone for 
SOD1 (CCS), an interaction that is mediated by an SOD1-like domain in CCS 
that  forms  a  dimer  with  the  zinc-containing  SOD1  subunit.  The  second 
modification  is  insertion  of  a  copper  ion  and  the  third  is  oxidation  of  the 73 
 
disulfide bond, both of which are mediated by CCS [138,139]. The completely 
folded monomer is then able to dimerize with another folded SOD1 subunit.  
The  unfolding  process  is  thought  to  proceed  through  a  two-state 
mechanism:  dimer  dissociation  followed  by  monomer  unfolding  [140]. 
Mutations to SOD1 destabilize the protein, presumably making this process 
more likely to occur [141]. The destabilization leads to a shift in the folding 
equilibrium  towards  increased  population  of  soluble,  partially  unfolded 
intermediate species [142]. The toxicity of mutant SOD1 may arise from such 
partially  unfolded  species  that  can  arise  either  via  incomplete  folding  and 
activation or via unfolding from an active state. The partially unfolded species 
present in vivo, however, are not well characterized.  
The metal cofactors in particular play a significant role in SOD1 stability 
and folding [55,140,143,144]. The metal-replete enzyme has an unfolding half-
life on the order of 200 years, whereas the apo protein unfolds in hours [140]. 
Zinc loss, in particular, dramatically decreases the stability of SOD1, and is 
thought to be the first metal lost as the protein unfolds [55,140]. Nevertheless, 
the metal content of SOD1 in vivo is often ignored or unknown. Techniques 
such  as  activity  gels  often  serve  as  surrogates  for  actual  metal-binding 
measurements,  although  the  activity  assay  demonstrates  only  the  ability  to 
inhibit the reaction of superoxide with an indicator molecule, not that copper is 
actually bound to the protein [145]. An additional problem is that high levels of 
metal  chelators,  such  as  millimolar  amounts  of  EDTA,  are  often  used  to 
prevent additional bands from appearing on an activity gel [30]. The bands are 
ascribed to spurious metal-binding to the protein, but the levels of chelators 
used may in fact impact the specifically-bound cofactors as well.  
Although the metal-binding of SOD1 is frequently ignored in vivo, there 
are several examples of SOD1 metal-binding playing a role in causing toxicity 
in cell culture models. The zinc chelating ability of the folded apo SOD1 was 
shown to mediate the toxicity of SOD1 to cultured human neuroblastoma cells 74 
 
[146]. The role of copper in toxicity has also been studied. The loss of zinc 
from SOD1  resulted  in  a  copper-containing  zinc-deficient protein  that  could 
induce  motor  neuron  apoptosis  in  cell  culture  similar  to  trophic  factor 
withdrawal [69,147]. The toxicity also required the production of nitric oxide, 
leading to peroxynitrite production. Zinc-deficient SOD1 can catalyze protein 
tyrosine nitration via peroxynitrite [57]. Crucially, the zinc-deficient protein was 
toxic  whether  or  not  it  carried  an  ALS-mutation,  evidence  that  may  help 
explain the mechanism of sporadic ALS.  
The lack of knowledge concerning the in vivo metal-binding of SOD1 is 
due in part to the difficulty in assessing the native metal-binding of a protein in 
vivo. This is especially true of SOD1, as copper and zinc are similar in mass 
and  electronic  structure.  The  intrasubunit  disulfide  bond  is  an  additional 
confounding factor that is intrinsically related to the metal-binding. One side of 
the disulfide linkage is located on the zinc-binding loop of the protein, making it 
necessary  to  understand  the  role  the  disulfide  bridge  may  play  in  metal-
binding. The level of disulfide reduced SOD1 protein in general has been the 
subject  of  debate,  as  different  levels  of  disulfide  reduction  in  transgenic 
animals  are  found  depending  on  the  methods  used,  although  the  metal 
content is not known [107,116,148].  
We  have  recently  developed  a  series  of  techniques  to  measure  the 
metal-binding and disulfide oxidation status of proteins from in vivo samples 
using high resolution mass spectrometry [113]. SOD1 can be extracted from 
small location-specific punches from disease-affected or non-affected areas of 
spinal  cord  tissue  from  transgenic  rats  or  mice.  A  C4  Ziptip®  allowed 
physiological  salts  to  be  washed  off,  enabling  the  detection  of  proteins  via 
electrospray mass spectrometry. We observed that almost half of the SOD1 
from the spinal cord of a wild-type SOD1 overexpressing transgenic mouse 
bound only a single zinc ion and was missing the copper cofactor. Almost 25% 
of that single metal SOD1 contained a reduced disulfide. Zinc-deficient SOD1 75 
 
was not observed. These results illuminate the need to understand how the 
metal-distribution of SOD1 is different in disease-affected G93A mice, as well 
as  how  it  might  change  as  the  disease  progresses.  We  present  here  the 
application  of  our  previous  methods  to  measure  SOD1  metal-binding  and 
disulfide  oxidation  status  from  G93A  and  wild-type  mouse  tissues  over the 
course of the disease progression. 
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4.3 Materials and Methods 
 
4.3.1 Animal Care and Use 
All  animal  studies  were  carried  out  with  strict  adherence  to  the 
recommendations in the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health. Oregon State University Laboratory Animal 
Resources Center personnel provided husbandry services in an Association 
for  Assessment  and  Accreditation  of  Laboratory  Animal  Care  accredited 
environment.  All  animal  handling  and  procedures  were  approved  and 
overseen  by  the  Institutional  Animal  Care  and  Use  Committee.  The  most 
commonly  used  transgenic  ALS  SOD1  model,  G93A  SOD  (B6SJL-
Tg(SOD1*G93A)1Gur/J)  mice,  grow  and  develop  normally  until around 110 
days  of  age  when  symptoms  of  the  disease  first  become  apparent.  The 
progression usually starts with an altered hind limb gait, proceeding in a few 
days with noticeable weight loss and partial paralysis. The end stage of the 
progression  was  complete paralysis of  the  hind  limbs,  typically  by  120-125 
days  of  age.  The  control  wild-type  SOD1-overexpressing  (B6SJL-
Tg(SOD1)2Gur/J)  mice  do  not  display  any  of  these  symptoms  and  are 
reported to contain about 60% of the SOD1 mRNA level of the G93A mice 
[23]. The mice were maintained in separate colonies by breeding hemizygous 
transgenic  males  to  non-transgenic  (B6SJLF1/J)  females.  New  transgenic 
male  mice  and  non-transgenic  female  mice  were  periodically  ordered  from 
Jackson  Labs  to  maintain  background  consistency  with  others  using  this 
model.  
Animals  sacrificed  for  tissue  harvest  were  placed  under  isofluorane 
anesthesia  followed  by  pericardial  perfusion  with  heparinized  PBS  and 
decapitation.  Brain,  kidney,  lung,  leg  muscle,  stomach  and  heart  were 
extracted via dissection and snap frozen in liquid nitrogen. The spinal cord 
was  removed  by  inserting  a  26  gauge  needle  into  the  base  of  the  spinal 77 
 
column and pushing PBS with a syringe to force the cord out the top. Although 
the cord came out intact, the roots were generally sheared off. Animals were 
sacrificed at 30 days, 60 days, 90 days, and 120 days or when they became 
symptomatic (110-120 days). The weakened structural integrity of the spinal 
cord in terminal animals (120-125 days) meant that the spinal cord could be 
easily damaged when removed. As a result, the animals chosen for the 120 
day age group for this study were sacrificed while symptomatic, but not yet 
terminal. Tissues were stored at -80 C prior to use. 
 
4.3.2 Tissue Measurements 
Four  types  of  SOD1  measurements  were  performed  on  the  tissues 
collected: SOD1 quantitation via mass spectrometry, determination of relative 
copper and zinc levels via high resolution mass spectrometry, disulfide bond 
oxidation status determination, and SOD1 extraction efficiency via reducing 
and  non-reducing  gels  and  Western  blots.  SOD1  quantitation  via  mass 
spectrometry was accomplished by including a known concentration of bovine 
SOD1 in the buffer. Additionally, the measurements were performed in the low 
resolution  linear ion  trap of our hybrid  LTQ-FT  instrument  due  to  concerns 
about overfilling the ICR cell when the standard bovine SOD1 was present and 
a desire to measure the level of apo SOD1, which was not observable with the 
m/z  cutoff  used  for  the  FT  measurements  (see  Chapter  3).  As  such, 
quantitation measurements only provided levels of apo, one-metal, and two-
metal SOD1. The disulfide oxidation status measurements were performed in 
the linear ion trap. The determination of copper or zinc bound to SOD1 was 
performed in the high resolution ICR cell.  
For spinal cord measurements, punches were taken from five 1 mm 
thick transverse sections from the lumbar region using a 300 μm biopsy punch 
(Zivic Instruments, Pittsburgh, PA, USA) with an air-filled syringe attached to 
the rear of the punch to expel the tissue as previously described  [113]. All five 78 
 
slices were laid out on an insulating plastic plate on top of dry ice to warm to 
about -20 °C as the tissue was too brittle at liquid nitrogen temperatures to 
manipulate. From each slice, one punch from each area (ventral left, ventral 
right, dorsal left, dorsal right) was taken with the biopsy punch; all 5 punches 
from each area were combined into one tube. The tissue from the left side was 
placed directly into 50 μL of 10 mM ammonium acetate with 10 mM diamide 
and centrifuged at 15000 rcf. The tissue from the right side was placed in a 
micro weigh boat (VWR #12577-060) and weighed on a Cahn 25 Automatic 
Electrobalance (Cerritos, CA, USA) with a sensitivity of 0.1 μg. After weighing, 
the  weigh  boat  was  flattened  in  the  top  of  a  microcentrifuge  tube  and  the 
tissue was spun down to the bottom of the tube containing 50 μL of 10 mM 
ammonium acetate. For brain measurements, 6 punches were taken from a 1 
mm thick coronal section of the (rostral) cortex region. Three punches were 
combined into one tube and prepared as described above for the spinal cord 
tissue. After centrifugation the supernatant was removed from the tissue pellet, 
separated into 10 μL aliquots, frozen and held in liquid nitrogen before mass 
spectrometry analysis. For all other tissues, single punches were thawed in 10 
L of 10 mM ammonium acetate, pH 5.2. 
Mass spectrometric analysis using a Ziptip was performed on a LTQ-FT 
Ultra  mass  spectrometer  (Thermo,  San  Jose,  CA,  USA)  as  previously 
described  (Chapter  3).  The  mass  spectrometry  running  solvent  was  either 
30:70 acetonitrile:water or 25:75 acetonitrile:water, depending on the tissue 
being assayed, delivered isocratically via a single Shimadzu HPLC pump. In 
both  cases  the  running  solvent  contained  100  μM  formic  acid  to  more 
efficiently ionize SOD1. The left-side tissue was analyzed in the ICR cell to 
provide high-resolution isotopic distributions that could be fit with our custom 
Matlab  programs  (Chapter  3).  Three  of  the  five  aliquots  were  run,  and 
individual aliquots were replaced if the fitting program was unable to find data 
to  fit.  The  right-side  tissue  was  analyzed  in  the  linear  ion  trap  to  provide 79 
 
quantitation data with bovine SOD1 used as an internal standard. One of the 
LTQ  aliquots  was  modified  on  the  Ziptip  with  MMTS  for  5  seconds  before 
being analyzed via the mass spectrometer to determine thiol oxidation status. 
For  determining  total  SOD1  concentration  spinal  cord,  brain,  kidney,  leg 
muscle,  heart  or  liver  was  sectioned  as  above  and  a  single  punch  was 
weighed on the electrobalance. After flattening the weigh boat in the top of the 
microcentrifuge tube, the tube was frozen for 3 seconds in liquid nitrogen. This 
was done because many of the non-CNS tissues would not release cleanly 
from the weigh boat upon centrifugation without freezing. The tube was then 
centrifuged and analyzed as above in the linear ion trap. This was repeated 
two more times for each tissue. We only report the levels of two-metal, one-
metal, and apo SOD1 in those tissues.  
 
4.3.3 Statistical Analysis 
  The level of zinc-deficient SOD1 was tested for statistical significance 
using Statgraphics (v. 16.1.03, StatPoint Technologies, Warrenton, VA, USA). 
Because  the  data  in  some  cases  did  not  fit  a  parametric  distribution,  The 
Kolmogorov-Smirnov test was used. 
 
4.3.4 Western Blot Analysis 
The amount of SOD1 released from tissue was verified by western blot 
analysis on non-reducing and reducing SDS-PAGE. We used both reducing 
and non-reducing gels to confirm the quantitation from the mass spectrometry 
analysis,  how  much  SOD1  remained  in  the  pellet  after  our  extraction 
procedure,  and  whether  thiol  or  non-thiol  crosslinked  oligomers  could  be 
observed from spinal cord tissue matched to that used for mass spectrometry 
analysis.  The  supernatants  from  three  punches  were  combined  to  provide 
enough sample per lane for the Western blot. The punches were thawed in 20 
μL  of  10  mM  ammonium  acetate  at  pH 5.1,  vortexed  for 10  seconds, and 80 
 
centrifuged  for  1  minute  at  15000  rcf.  The  tissue  supernatant  and  pellet 
fractions were separated, and the pellet was rinsed with an additional 10 μL of 
thaw buffer. The rinse was combined with the supernatant. The supernatant 
fraction was diluted with 5X Laemmli buffer, bringing the Laemmli buffer to a 
1X  concentration.  The  pellet  was  brought  up  to  the  same  volume  as  the 
supernatant fraction with 1X Laemmli buffer [100]. For the non-reducing gels, 
Laemmli  buffer  without  β-mercaptoethanol  was  used.  The  samples  were 
heated for 5 min at 95 °C. Samples were then run on a 10% SDS-PAGE at 
150 V for 60 min in a Bio-Rad Mini Protean II system. Gels were transferred to 
a polyvinylidene fluoride membrane (Bio-Rad Product No. 162-0177) for 60 
min at 100 V. SOD1 was detected using rabbit polyclonal antibodies raised in 
our  laboratory  against  human  SOD1  (1:10000).  Affinity-purified  antibodies 
retained cross reactivity with mouse and rat SOD1. The secondary antibody 
was  goat  anti-rabbit  IgG  heavy  plus  light  chain  horseradish  peroxidase 
conjugate (Bio-Rad No. 170-6515).  
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4.4 Results 
 
4.4.1 SOD1 Distribution and Metal Content in Tissues 
The total amount of SOD1 was higher in wild-type mice than in G93A 
mice in spinal cord, brain, kidney and liver, whereas the reverse was true for 
the muscle tissues (Figures 4.1 and 4.2). The majority of the SOD1 contained 
both copper and zinc with the amount missing one metal being largest in the 
spinal cord and brain tissues of both G93A and wild-type SOD1 transgenic 
mice.  In  these  tissues,  one-metal  forms  accounted  for  20-30%  of  the  total 
SOD1 in G93A mice, but 45-55% in wild-type mice. The SOD1 missing one-
metal comprised  less  than  15%  in  the  other tissues. These  measurements 
were the average of 3 independent tissue punches, likely contributing to the 
high variability observed in some cases. The amount of apo-SOD, which is 
missing both copper and zinc, was less than 5% in all tissues assayed.  
The  high  resolution  of  the  FT-ICR  mass  spectrometer  allowed  the 
theoretical isotopic distributions for zinc and copper-containing SOD1 to be fit 
to isotopically resolved spectra of SOD1. The amounts of each SOD1 metal-
state were 30% lower than in Figures 4.1 and 4.2; the extraction method for 
assays to determine the metal bound to SOD1 contained one less freeze-thaw 
step  due  to  concerns  about  the  stability  of  one-metal  SOD1s.  In  initial 
experiments, the one metal-containing SOD1 fit best to only zinc-containing 
SOD1  for  both  genotypes,  with  no  measurable  copper-containing  SOD1 
(Figure  4.3A,C).  Close  examination  of  the  m/z  spectra  also  showed  small 
evidence of oxidation of the SOD protein, manifested as the addition of 1-3 
oxygens  to  the  protein.  We  did  not  observe  glutathione  adducts  or  other 
modifications to the C111 thiol. Such modifications were readily detected in 
recombinant SOD1, particularly when subjected to treatments adding copper 
to metal-deficient SOD involving dialysis (data not shown).  
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4.4.2 Diamide Prevents Copper Loss from Zinc-deficient SOD1 
We  were  initially  unable  to  measure  any  copper-containing,  zinc-
deficient  SOD1  from  the  spinal  cord,  even  in  early  symptomatic  G93A 
transgenic  animals  (Figure  4.3A).  Because  of  the  toxicity  of  zinc-deficient 
SOD1  to  motor  neurons  in  cell  culture,  we  tested  whether  tissues  might 
contain  compounds  that  would  remove  copper  from  zinc-deficient  SOD1 
during isolation by adding recombinant zinc-deficient SOD1. The copper was 
in fact quickly removed from zinc-deficient SOD1 and ultrafiltration showed the 
copper–removing activity would pass through a 3-kDa membrane. A variety of 
reagents  and  methods  were  tested  to  prevent  the  loss  of  copper  from 
recombinant  zinc-deficient  SOD.  Inclusion  of  the  sulfhydryl  oxidant  diamide 
directly in the thaw buffer used for the frozen tissue punches was the most 
effective at preserving copper in recombinant zinc-deficient SOD1. Diamide 
treatment  also  effectively  oxidized  the  intracellular  disulfide  bond  in  SOD1, 
further simplifying the isotopic analyses by eliminating overlapping disulfide-
reduced species from the mass spectrum (Chapter 3).    
With the inclusion of diamide, copper-containing, zinc-deficient SOD1 
could be measured in the spinal cord, particularly in G93A SOD1 mice (Figure 
4.3B). Less was found in wild-type SOD1 mice where the amounts observed 
were  generally  close  to  background  (Figure  4.3C).  Separate  experiments 
using recombinant SOD1s showed that diamide treatment had no effect on the 
isotopic distribution of Cu,Zn SOD1, copper-deficient, zinc-containing SOD1 or 
apo-SOD1 for either wild-type, ALS mutant or C111S pseudo-wild-type SOD1 
proteins. Thus, the appearance of zinc-deficient, copper-containing SOD1 in 
tissues was unlikely to be caused by the oxidation of another moiety on SOD1 
that might thereby have decreased the mass by two Daltons to overlap with 
that of zinc-deficient SOD1. It also did not result in a  significant amount of 
zinc-deficient SOD1 becoming detectable in wild-type SOD transgenic tissues. 83 
 
Importantly, addition of diamide even 2 minutes after thawing the punch in 
buffer resulted in no detectable copper-containing SOD1.   
 
4.4.3 Metal Content of G93A SOD1 from Spinal Cord 
In G93A mice, CuZn SOD1 was 6.3 ± 0.8 pmol/mg tissue at 30 days old 
and increased to 16 ± 1.5 pmol/mg tissue at 120 days old in ventral spinal cord 
(Figure  4.4).  Only  3-5%  of  the  Cu,Zn  SOD1  contained  a  reduced  disulfide 
bond,  which  was  unchanged  as  the  mice  aged.  Zinc-containing,  copper-
deficient SOD1 was the major species in the ventral spinal cord, particularly in 
60- and 90-day-old mice. A larger fraction of the disulfide in zinc-containing 
SOD1 (35%) was reduced compared to Cu,Zn SOD1. 
The amount of copper-containing, zinc-deficient SOD1 was consistent 
across all ages in the ventral and dorsal spinal cord, ranging from average 
concentrations of 0.6 to 0.7 pmol/mg tissue. The requirement for diamide to 
retain copper prevented measuring the proportion of zinc-deficient SOD1 that 
contained a reduced disulfide bond. Apo SOD1 ranged between 0.1 ± 0.02 
pmol/mg tissue to 1.4 ± 0.2 pmol/mg tissue. These low levels of apo-SOD1 
suggest that there was not a substantially larger pool of zinc-deficient SOD1 
that had shed its copper during isolation. 
The metal contents of SOD1 in the dorsal horn essentially mirrored the 
ventral  spinal  cord.  The  concentration  of  total  SOD1  peaked  at  27  ±  6.1 
pmol/mg tissue (Figure 4.5). The concentration of zinc-containing SOD1 in the 
dorsal horn was large compared to other tissues, though the fraction of zinc-
containing SOD1 was less than in ventral spinal cord (30-40%). 
 
4.4.4 Metal Content of Wild-type SOD1 from Spinal Cord 
The  ventral  and  dorsal  spinal  cord  from  wild-type  mice  contained 
substantially more SOD1 protein at 30 and 60 days than G93A mice, but total 
SOD1 levels became comparable to those found in G93A mice at later ages 84 
 
(Figure  4.6  and  4.7). This did  not  hold  true  when  we  made  more  rigorous 
attempts to extract all of the SOD1, in which case the wild-type animals had 
larger amounts of SOD1, although the proportions of the number of metals 
bound to SOD1 remained the same (data not shown). Remarkably, wild-type 
SOD1 contained substantially more zinc-containing SOD1 at all ages from 30 
to 120 days than G93A mice. Furthermore, 45% of the zinc-containing SOD1 
had a reduced disulfide bond at all ages, which was far greater than found in 
G93A SOD1 spinal cord. This was statistically significant by one-way ANOVA 
(F-ratio 47.99, p-value <0.001 at the 95% confidence interval). CuZn SOD1 
levels were similar to those found in G93A mice, around 10-13 pmol/mg tissue 
in both regions and at all ages. The disulfide of wild-type CuZn SOD1 was only 
6-7% reduced, compared to 3-5% for the G93A mice. Apo wild–type SOD1 
ranged from 0.3 pmol-mg tissue in 30-day-old mice to 1.7 pmol/mg tissue in 
120-day-old mice. 
The  amount  of  copper-containing  wild-type  SOD1  was  significantly 
lower than the G93A mice and was consistent at all ages in both ventral and 
dorsal spinal cord, about 0.1 pmol/mg tissue. The standard error of mean of all 
of the copper-containing wild-type SOD1 measurements was extremely high 
due  to  the  levels  measured  being  close  to  the  noise  level.  Thus,  the 
distribution of zinc-deficient SOD1 was very close to 0 and the fitting program 
did  not  allow  negative  numbers  for  any  value.  The  distribution  was  non-
parametric as a result and so the Kolmogorov-Smirnov test was used to test 
for significance. Many of the individual wild-type SOD1 replicate spectra did 
not fit any copper in the one-metal SOD1 peak. 
 
4.4.5 Amount of SOD1 Assessed by Western Blots 
  The  release  of  SOD1  from  spinal  cord  tissues  punches  was  also 
monitored  by  western  blot  as  a  way  to  verify  some  aspects  of  our  mass 
spectrometry  assays  (Figure  4.8).  Spinal  cord  tissue  from  representative 85 
 
animals of the cohort used for the mass spectrometry assays was used. The 
gels  were  run  both  with  (reducing)  and  without  (non-reducing)  β-
mercaptoethanol  to  account  for  and  be  able  to  monitor  the  presence  of 
disulfide  reduced  species.  We  also  used  longer  exposures  to  determine  if 
small amounts of oligomerized SOD1 was present (Figure 4.9). Pseudo-wild-
type C111S SOD1 was used for a standard curve. 
Rough quantitation of the amount of SOD1 in the soluble fraction by 
eye  agreed  well  with  the  mass  spectrometry  measurements,  reflecting  the 
population  of  SOD1  that  is  extracted  via  the  more  gentle  method.  For 
example, the SOD1 concentration in the 30 day old G93A mouse used for the 
western blot was 15.1 pmol/mg tissue via mass spectrometry. The amount in 
the pellet fraction was ~5-15% of the total SOD1, which generally matched the 
increase  in  SOD1  concentration  from  the  spinal  cord  observed  when  we 
included the additional freeze/thaw cycle to ensure complete extraction. We 
could not see any higher molecular weight species at 1-3 second exposure 
times. However, longer exposure times revealed the presence of a series of 
higher molecular weight bands immunoreactive for SOD1. The bands were 
more intense in the non-reducing gel, as well as generally tending to increase 
with age. 
 
4.4.6 SOD1 in Cerebral Cortex 
In G93A SOD1 mice, the brain contained similar total SOD1 levels as 
the spinal cord (Figure 4.10). The majority of the SOD1 contained copper and 
zinc in the cerebral cortex with 2-3 pmol/mg tissue of zinc-containing SOD1. 
The concentrations of copper-containing, zinc-deficient SOD1 in cortex were 
roughly equivalent to those found in spinal cords. 
The  zinc-containing  SOD1  from  wild-type  brain  cortex  was  8-11 
pmol/mg  tissue,  which  was  substantially  higher  than  found  in  G93A  SOD1 
cortex and paralleled the results from spinal cord (Figure 4.11). The SOD1 in 86 
 
brain contained a similar fraction of disulfide-reduced protein as found in spinal 
cords and significantly less copper-containing SOD1 compared to G93A SOD1 
brain of spinal cord. The amount of apo SOD1 was less than 2 pmol/mg tissue 
in brain at all ages for both genotypes (Figures 4.10-4.11). 
 
4.4.7 Metal Content of SOD1 in Leg Muscle 
Total  SOD1  from  G93A  muscle  stayed  relatively  consistent  (35-39 
pmol/mg tissue) for 30-90 days, but then increased to 52 pmol/mg tissue at 
120 days old mice (Figure 4.12). At this stage, the muscle was undergoing 
severe shrinkage due to the disease. Total SOD1 concentrations from wild-
type muscle (35-42 pmol/mg tissue) were similar to that in G93A SOD1 mice 
and did not rise at 120 days. CuZn SOD1 accounted for 70-80% present in 
muscle at all ages in G93A and wild-type mice with ~5% containing a reduced 
disulfide bond. As in the spinal cord and in the brain, there was more one-
metal SOD1 in the leg muscle in wild-type mice than in G93A mice (30% in the 
wild-type, 15% in the G93A mice) (Figure 4.13). The low signal-to-noise ratio 
in muscle tissue made the fit of copper or zinc in the one-metal peak unreliable 
(RMS>6%), thus we used the linear ion trap data and reported only the total 
amount of one-metal SOD1. 
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4.5 Discussion 
 
The mass spectrometry assay allowed the binding of copper and zinc 
as well as reduction of the  C57-C146 disulfide bridge to be simultaneously 
determined  in  SOD1  from  specific  spinal  cord  regions  of  transgenic  mice, 
yielding the first quantitative distribution of partially unfolded intermediates of 
SOD1  throughout  ALS  disease  progression.  Far  more  soluble,  partially 
unfolded intermediates of SOD1 reside in the ventral gray spinal cord than in 
dorsal gray spinal cord, brain, muscle, heart, liver, kidney, lung or stomach. 
The surprising result was that wild-type SOD mice had substantially more of 
every partially folded intermediate SOD1 species than in G93A SOD1 mice, 
with the sole exception of zinc-deficient SOD (Figure 4.4-4.7 and 4.14). 
 The concentrations of SOD1 protein in both wild-type and G93A SOD1 
are astonishing in all tissues assayed. The reporting of SOD1 as picomols 
protein per milligram-wet-weight corresponds to an equivalent concentration in 
micromolar protein. Thus, the average total SOD1 concentration in the ventral 
horn of the spinal cord corresponded to 38 μM in G93A mice and 69 μM in 
wild-type mice at 60 days of age. Western blot data reported by Jonsson et al. 
yields even higher estimates in 100 day old mice of 69 μM in the total mouse 
spinal cord of G93A mice and 101 μM in wild-type mice [107]. Clearly SOD1 is 
highly  overexpressed  to  the  point  where  its  cellular  concentration  is 
comparable  to  that  of  molecular  oxygen  in  tissues.  Furthermore,  these 
estimates  of  SOD1  concentrations  average  multiple  cell  types  together. 
Immunohistology reveals SOD1 is several fold higher in motor neurons relative 
to the surrounding neuropil [149,150]. SOD1 is also present in the axons of 
motor neurons, which may constitute 99% of the volume of a motor neuron 
that extends beyond the ventral gray horn [151,152]. 
The average concentration of SOD1 is even higher in the heart and 
livers of 60 day-old G93A mice, corresponding to ~69 μM and 83 μM Cu,Zn 88 
 
SOD1 respectively. In non-CNS tissues, 80-90% of the SOD1 was mature, 
Cu,Zn  SOD1  desite  having  higher  SOD1  concentrations  than  in  brain  and 
spinal cord. This suggests that copper import into the CNS is much slower 
than in other tissues. Indeed, the turnover of copper in rat brain is estimated to 
have a half-life of over 400 days [153]. Zinc import is also closely regulated in 
the CNS. Excessive free zinc accumulation in the nanomolar range has been 
shown to be toxic in the CNS [154,155].  
Several groups have measured the zinc and copper levels in transgenic 
mouse spinal cord. Tokuda et al. found 36 μM copper and 66 μM zinc in 56 
day old G93A mice via inductively coupled plasma mass spectrometry. Lelie, 
et  al.,  found  significantly  higher  amounts  of  copper  and  zinc  in  end-stage 
animals, 95 and 214 μM respectively, amounts sufficient to achieve full copper 
and zinc incorporation into the SOD1. This difference might reflect the different 
age of the mice and in part the G93A line used as Tokuda  et al. used the 
B6SJL-Tg(SOD1-G93A)
dl  1Gur/J  line.  This  line  contains  about  30%  fewer 
copies of the G93A transgene and therefore express less SOD1, which may 
reduce the import of copper and zinc into the spinal cord of these animals 
[156].  
The increased amount of zinc-containing SOD1 in the wild-type mice 
suggests that sequestering of zinc is not sufficient for toxicity as has been 
suggested [146]. Johansson et al. found the ability of apo SOD1 to deplete 
zinc  from  cell  culture  growth  media  was  toxic  to  cultured  human 
neuroblastoma cells. However, the total level of zinc reported by Lelie, et al. 
indicates that the SOD1 concentration in the spinal cord would require only 
20% of the available zinc to be fully zinc replete. Even using the lower amount 
of zinc determined by Tokuda et al., fully zinc replete SOD1 does not require 
all of the available zinc in the spinal cord. This is borne out by the fact that the 
majority  of  the  protein  does  contain  zinc,  indicating  zinc  is  not  limiting. 
However,  what  is  not  clear  from  the  data  is  which  direction  of  the  SOD 89 
 
maturation/unfolding pathway the various intermediates are moving towards. 
The folding pathway of the in vitro protein usually involves incorporation of zinc 
as one of the first steps, consistent with zinc-containing SOD1 representing 
immature SOD1 that has not received copper yet. 
The mass spectrometry assay also reveals much about modifications to 
SOD1  that  we  did  not  see.  Oxidation  and  glutathionylation  have  been 
hypothesized  to  contribute  to  SOD1-linked  toxicity  [157-159].  These 
modifications are typically thought to occur on the cysteine residue located at 
position 111, possibly with the involvement of ectopic copper binding at this 
location [160]. In our assay, such modifications would be readily apparent by 
the increase in mass the addition of oxygen or glutathione would add to the 
protein. However, we observed no evidence of glutathionylation to SOD1 in 
any of the tissues assayed via mass spectrometry. We did see small amounts 
of  SOD1  that  contained  1-3  additional  oxygens.  However,  the  SOD1  with 
additional oxygens was less than 2% of the total protein and was discernible in 
only about 30% of the animals. It was equally abundant in wild-type SOD1-
expressing mice as in G93A SOD1 mice. The oxidized species could overlap 
with our measurement of disulfide reduction, slightly increasing the amount of 
one-metal  SOD1  found  to  be  reduced.  However  this  only  resulted  in  an 
increase of 2% zinc-containing SOD1 reduced. 
The  difference  in  SOD1  total  concentrations  depending  on  the 
extraction method from tissue is interesting because we did not observe this 
previously when working with rat tissue [113]. The metal cofactors play such a 
significant  role  in  the  stability  of  SOD1  that  partially  unfolded  intermediate 
species, which may be missing one or both metals, are likely to be marginally 
stable.  Indeed  we  have  already  observed  that  diamide  is  a  necessary 
component of the thaw buffer in order to measure zinc-deficient SOD1. We 
have also noticed that it is difficult to prepare recombinant G93A zinc-deficient 
SOD1, indicating that it is less stable than CuZn SOD1 and quickly inactivated 90 
 
in tissue lysates. As such, we designed an extraction protocol that was as 
gentle as possible, essentially only involving a single freeze-thaw step. The 
fact  that a more  rigorous  extraction  protocol involving  an  additional freeze-
thaw results in the release of more SOD1 from the tissue suggests that the 
amounts of partially unfolded intermediates of SOD1 measured with the first 
method are underestimates of the actual tissue concentration.  
In contrast to our previous work, we observed an increased proportion 
of the SOD1 from the transgenic mouse spinal cord in the pellet fraction via 
Western blots [113]. We did not observe this in the rat model animals. It may 
be that this is a species-specific effect that will require more investigation in 
the mouse model. The blots did reveal when grossly overexposed, also unlike 
the  rats,  small  amounts  of  higher  molecular  weight  oligomeric  species  of 
SOD1 existed and could be observed if the blot was exposed for long enough. 
However, the proportion was exceedingly minor compared to the total SOD1, 
and was generally higher in the wild-type mice until the late stages of disease 
in the G93A mice, suggesting it is not relevant to disease toxicity. The higher 
molecular  weight  species  may  represent  disulfide  cross-linked  versions  of 
SOD1. The level of disulfide reduced SOD1 was significantly higher in wild-
type mice than in G93A mice and this may tend to lead to the formation of 
disulfide cross-linked species in small amounts.  
Zinc-deficient  SOD1  is not  stable  in  spinal  cord  samples,  which  has 
made  detection  challenging.  It  could  only  be  measured  by  including  the 
sulfhydryl oxidant diamide directly in the buffer used to thaw tissue punches. If 
the  addition  of  diamide  was  delayed  for  even  30  seconds  after  the 
centrifugation step, zinc-deficient SOD1 could not be measured.  Diamide has 
two major effects in this assay. Diamide oxidizes cysteines C57 and C146 to 
reestablish  the  disulfide  bond  that  stabilizes  the  zinc-binding  loop  as  we 
previously described (Chapter 3). Because copper is on average two Daltons 
smaller than zinc, the two additional hydrogens added by the reduction of the 91 
 
disulfide  makes  thiol-reduced,  zinc-deficient  SOD1  overlap  completely  with 
thiol-oxidized,  copper-deficient  SOD1  in  the  mass  spectrometer.  Hence, 
addition  of  diamide  reversed  that  overlap,  allowing  any  thiol-reduced  zinc-
deficient SOD1 to become measurable by the mass spectrometer. 
The  second  major  action  of  diamide  is  oxidation  of  a  low  molecular 
weight  compound  in  spinal  cord  that  removes  copper  from  zinc-deficient 
SOD1. A likely candidate for this compound is glutathione, which is quickly 
oxidized by diamide to glutathione disulfide [118]. Glutathione is an excellent 
copper  chelator  as  well  as  a  sulfhydryl  reductant  [87].  We  had  previously 
found that glutathione removed copper from recombinant zinc-deficient SOD1 
in vitro and could remove copper from Cu,Zn SOD1 in addition to reducing the 
disulfide bond.  
Among many other antioxidant functions, glutathione may also serve as 
a  major  protective  factor  by  removing  zinc-deficient  SOD1.  Motor  neurons 
depend on astrocytes to synthesize glutathione [161]. Knockouts of parts of 
the glutathione synthetic pathway dramatically accelerate the disease when 
crossed  with  G93A  SOD1  overexpressing  mice,  with  death occurring  in  60 
rather than 130 days [33]. In contrast, activation of the transcription factor Nrf2 
that increases GSH synthesis is protective in both astrocyte/motor neuron co-
cultures and in G93A mice [34,35]. Depletion of glutathione levels in the motor 
neuron or interruption of the supply of glutathione precursors from astrocytes 
may affect the onset of toxicity by failing to prevent the accumulation of zinc-
deficient SOD1. 
We have previously shown that the copper in recombinant zinc-deficient 
SOD1 catalyzes tyrosine nitration when delivered to motor neurons in culture 
[70].  More  recent  unpublished  results  (A.G.  Estévez,  University  of  Central 
Florida) show that as little as 0.5 μM of purified zinc-deficient SOD1 delivered 
directly to cultured motor neurons is sufficient to induce motor neuron death. 
The G93A mouse spinal cord and brain contained zinc-deficient SOD1 close 92 
 
to or above this value while the wild-type SOD1 mouse spinal cord and brain 
were consistently well below the threshold (Figure 4.15). Zinc-deficient SOD1 
was also present in mice at 30 days of age, well before onset of observable 
symptoms  in  the  G93A  mice.  However,  spinal  cord  pathology  has  been 
reported in these animals as early as 30 days of age, along with subtle signs 
of injury in the motor cortex [162].  
In G93A SOD1 mice, zinc-deficient SOD1 was also found in the dorsal 
spinal cord and brain in amounts similar to ventral spinal cord. The actual toxic 
effect may occur early on while the phenotypic effects are not observed until 
later [162]. Activation of cell death in motor neurons by zinc-deficient SOD1 
depended  upon  the  simultaneous  generation  of  nitric  oxide  to  generate 
peroxynitrite [94]. Thus the animals may carry zinc-deficient SOD1 throughout 
their lifespan, but realize minimal injury without the presence of nitric oxide. Ye 
et al. showed that motor neuron death from trophic factor deprivation or from 
expression of mutant SOD1 depended upon tyrosine nitration [71]. Raoul et al. 
have described a Fas-ligand signaling pathway specific to motor neurons that 
involves the upregulation of neuronal nitric oxide synthase and a vicious cycle 
involving chronic, low-level activation of a Fas/nitric oxide feedback loop that 
eventually activates cell death in motor neurons [163,164]. Thus, zinc-deficient 
SOD1  appears  to  amplify  nitrative  stress  to  levels  that  eventually  activate 
death cascades in motor neurons. 
A  crucial  next  step  for  this  research  is  to  use  the  tools  we  have 
developed  to  examine  other  ALS-model  animals.  Four  other  SOD1-
overexpressing  ALS  mouse-models  are  commercially  available,  thus 
representing  important  targets  in  which  to  determine  if  the  trends  we  have 
noted  are  also  present.  Our  mass  spectrometry  assay  also  enables 
measurements of the metal-binding distribution from modified disease models 
such as CCSxG93A SOD1 overexpressing animals, which develop and die 
from  ALS  symptoms  by  30  days  of  age  [32].  Such  measurements  are 93 
 
important  for  understanding  how  CCS  hastens  disease  onset.  Additionally, 
knockdown of a portion of the glutathione synthesis pathway also increases 
disease onset, to 50 days of age [33], and our results reveal the possibility that 
glutathione may be a key player in the disease progression. Experiments to 
measure the levels of partially unfolded intermediates in these animals are 
therefore essential objectives to determine how glutathione may influence the 
disease. The distributions of intermediates also represent important targets for 
therapeutic interventions. Compounds that alter the levels of partially unfolded 
intermediates,  particularly  by  removing  zinc-deficient  SOD1,  are  important 
areas  of  research  for  developing  treatments  for  ALS.  Finally  the  methods 
reported here could be applied to protein post-translational modifications in 
other  neurodegenerative  disorders,  potentially  providing  a  greater 
understanding of how such modifications may contribute to disease pathology. 
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4.7 Abbreviations 
 
  SOD1,  Cu,Zn  superoxide  dismutase;  ALS,  amyotrophic  lateral 
sclerosis; CCS, copper chaperone for SOD1; wild-type, wild-type; HPLC, high 
performance  liquid  chromatography;  FT-ICR,  fourier  transform  ion  cyclotron 
resonance;  MMTS,  S-methyl  methanethiosulfonate;  SDS-PAGE,  sodium 
dodecyl sulfate polyacrylamide gel electrophoresis; GSH, glutathione. 
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Figure 4.1 SOD1 metal state levels from various tissues from 60 day old 
G93A mice. The total amount of SOD1, broken down by metal state, was 
measured from 6 different tissues using 3 replicates from each of three 60 day 
old G93A mice: spinal cord (Spnl Crd), brain (Brn), Kidney (Kdny), Leg Muscle 
(Lg Mscl), Heart (Hrt), Liver (Lvr). Error bars are ± SEM. 
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Figure 4.2 SOD1 metal state levels from various tissues from 60 day old 
wild-type mice. The total amount of SOD1, broken down by metal state, was 
measured from 6 different tissues using 3 replicates from each of three 60 day 
old  wild-type  mice:  spinal  cord  (Spnl  Crd),  brain  (Brn),  Kidney  (Kdny),  Leg 
Muscle (Lg Mscl), Heart (Hrt), Liver (Lvr). Error bars are ± SEM. 
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Figure 4.3 Impact of diamide. The one-metal peak on the left can contain 
either copper (blue) or zinc (green). The CuZn peak on the right can contain 
copper in the +2 (green) or +1 (magenta) oxidation state. A. A punch from the 
ventral spinal cord of a G93A mouse without diamide in the thaw buffer. B. A 
punch from the same animal with 10 mM diamide in the thaw buffer. C. A 
punch from the ventral spinal cord of a wild-type mouse with 10 mM diamide in 
the thaw buffer. Note that the wild-type SOD1 spectra are 14 Da less in mass 
due to the absence of the CH2 introduced by the G93A mutation.   99 
 
 
 
Figure 4.4 SOD1 distribution in the ventral spinal cord of G93A mice. The 
SOD1 at 30, 60, 90, and 120 days in G93A mouse spinal cord is broken down 
by metal state: apo (grey), copper-containing (cyan), zinc-containing (blue), 
and CuZn (green). The proportion of each species that is disulfide reduced is 
represented by the darker-shaded bar. All error bars are ± the standard error 
of mean (SEM).    100 
 
 
Figure 4.5 SOD1 distribution in the dorsal spinal cord of G93A mice. The 
SOD1 at 30, 60, 90, and 120 days in G93A mouse spinal cord is broken down 
by metal state: apo (grey), copper-containing (cyan), zinc-containing (blue), 
and CuZn (green). The proportion of each species that is disulfide reduced is 
represented by the darker-shaded bar. All error bars are ± SEM.  
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Figure 4.6 SOD1 distribution in the ventral spinal cord of wild-type mice. 
The  SOD1  at  30,  60,  90,  and  120  days  in  wild-type  mouse  spinal  cord  is 
broken  down  by  metal  state:  apo  (grey),  copper-containing  (cyan),  zinc-
containing (blue), and CuZn (green). The proportion of each species that is 
disulfide reduced is represented by the darker-shaded bar. All error bars are ± 
SEM. 
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Figure 4.7 SOD1 distribution in the dorsal spinal cord of wild-type mice. 
The  SOD1  at  30,  60,  90,  and  120  days  in  wild-type  mouse  spinal  cord  is 
broken  down  by  metal  state:  apo  (grey),  copper-containing  (cyan),  zinc-
containing (blue), and CuZn (green). The proportion of each species that is 
disulfide reduced is represented by the darker-shaded bar. All error bars are ± 
SEM.   103 
 
 
Figure  4.8  Western  blots  of  reducing  and  non-reducing  gels  of  spinal 
cord punches. The amount of SOD1 released from the tissue punches was 
monitored by reducing and non-reducing gels followed by Western blot with 
our anti-SOD1 antibody. Blot 1 is the pellet (P) and supernatant (S) fraction 
from a 30 day old G93A and wild-type and a 60 day old G93A and wild-type 
mice, followed by a standard curve using C111S SOD1 (as read left to right). 
The standard curve was 10 ng (0.6 pmol), 30 ng (1.9 pmol), 100 ng (6.3 pmol), 
300 ng (19 pmol), and 1000 ng (63 pmol). Blot 3 contains the same only the 
gel was run without β-mercaptoethanol. Blots 2 and 4 are identical treatment 
of tissue from 90 and 120 day old animals. 
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Figure  4.9  Overexposed  Western  blots  of  reducing  and  non-reducing 
gels of spinal cord punches. The same blots as Figure 4.7 were exposed for 
longer periods to look for low abundance species of SOD1.  
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Figure 4.10 SOD1 distribution in the cerebral cortex of G93A mice. The 
SOD1 at 30, 60, 90, and 120 days in G93A cerebral cortex is broken down by 
metal state: apo (grey), copper-containing (cyan), zinc-containing (blue), and 
CuZn  (green).  The  proportion  of  each  species  that  is  disulfide  reduced  is 
represented by the darker-shaded bar. All error bars are ± SEM.   106 
 
 
Figure 4.11 SOD1 distribution in the cerebral cortex of wild-type mice. 
The SOD1 at 30, 60, 90, and 120 days in wild-type mouse cerebral cortex is 
broken  down  by  metal  state:  apo  (grey),  copper-containing  (cyan),  zinc-
containing (blue), and CuZn (green). The proportion of each species that is 
disulfide reduced is represented by the darker-shaded bar. All error bars are ± 
SEM. 
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Figure 4.12 SOD1 distribution in the leg muscle of G93A mice. The SOD1 
at 30, 60, 90, and 120 days in G93A mouse leg muscle is broken down by 
number  of  metals  bound:  no-metals  (grey),  one-metal  (blue),  two  metals 
(green).  The  proportion  of  each  species  that  is  disulfide  reduced  is 
represented by the darker-shaded bar. Each age is 3 measurements of one 
representative animal. All error bars are ± 1 standard deviation. 
 
   108 
 
 
Figure 4.13 SOD1 distribution in the leg muscle of wild-type mice. The 
SOD1 at 30, 60, 90, and 120 days in wild-type mouse leg muscle is broken 
down  by  number  of  metals  bound:  no-metals  (grey),  one-metal  (blue),  two 
metals  (green).  The  proportion  of  each  species  that  is disulfide  reduced  is 
represented by the darker-shaded bar. Each age is 3 measurements of one 
representative animal. All error bars are ± 1 standard deviation. 
 
   109 
 
 G93A         Wild-type 
 
Figure  4.14  Partially  unfolded  intermediates  of  SOD1  in  transgenic 
mouse spinal cord. The average levels of each intermediate from the 60 day 
old mouse spinal cords are proportionally represented by the colored boxes, 
with  the  lighter  fraction  representing  the  proportion  of  each  species  that 
contains a reduced disulfide bond.    110 
 
 
 
Figure  4.15  Levels  of  zinc-deficient  SOD1  in  transgenic  mouse  spinal 
cord. The amount of zinc-deficient SOD1 in G93A and wild-type ventral spinal 
cord at 4 different ages are represented by each colored marker and line. The 
measurement of pmol SOD1/mg tissue roughly corresponds to a concentration 
in micromolar. 0.5 μM zinc-deficient SOD1 was necessary for toxicity to motor 
neurons in vitro. Error bars represent ± SEM. 
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Chapter 5 
 
 
Conclusions and Outlook 
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5.1 Summary 
 
  My dissertation presents the development of methods to measure the 
metal-binding  of  SOD1  from  transgenic  disease-model  tissue.  The 
development of a Ziptip-based assay that allowed rapid quantification of SOD1 
from small punches of spinal cord tissue (Chapter 2), and the extension of that 
assay to high resolution mass spectrometry (Chapter 3) led to a larger-scale 
characterization of the metal-binding of SOD1 in G93A and wild-type mice at 
several time points (Chapter 4). We made several key observations, including 
the high level of zinc-containing SOD1 in both genotypes, the higher level of 
disulfide reduced SOD1 in the wild-type animals, that G93A mice contained 
more  copper-containing  SOD1  at  all  ages and  in  all  regions  than  wild-type 
mice, and that apo SOD1 did not seem to be an abundant species relative to 
the other forms of SOD1 in any region tested. The wider impacts of this work 
and the future directions of the research are summarized below. 
 
5.2 Impacts 
 
  A  critical  component of  the  work presented  in my  dissertation  is  the 
development  of  a  series  of  methods  to  measure  modifications  to  intact 
proteins  via  mass  spectrometry.  These  methods  were  developed  for 
determining the metal-binding of SOD1 from tissue, but can also be applied to 
other  proteins.  We  have  used  the  Ziptip  as  an  interface  to  observe  many 
recombinant proteins, including CCS, GFP, the coat-protein from turnip yellow 
mosaic virus, symerythrin, and cysteine dioxygenase. The Ziptip is particularly 
useful as the protein can remain in high strength buffers or salts yet still be 
amenable  to  electrospray  mass  spectrometry.  Jared  Williams,  a  current 
graduate  student  in  the  lab,  has  even  succeeded  in  using  8  M  urea  and 
guanidine to probe protein denaturation via mass spectrometry.  Versions of 113 
 
the  C4  Ziptip  with  different  chromatography  material,  such  as  C18,  are 
available that could enable many other proteins to be studied in this manner. 
The  Ziptip  method  provides  similar  information  as  an  SDS-PAGE  gel  or 
Western  blot,  but  it  is  more  rapid,  provides  better  resolution,  and  is  more 
sensitive. The assay provides anyone with access to a mass spectrometer the 
means to rapidly assess the molecular weight of a protein of interest along 
with any modifications that may be present. 
  The ability to use high resolution mass spectrometry to parse small-
mass-difference  protein  modifications  extends  the  utility  of  the  Ziptip  assay 
even  further.  Small  changes  to  a  protein  can  be  monitored  even  if  they 
represent  only  a  fraction  of  the  protein  under  investigation.  This  technique 
could be used to monitor amino acid deamidation (Δ1 Da), disulfide formation 
or reduction (Δ2 Da), or several amino acid substitutions that result in mass 
differences of less than 5 Da, among other modifications. The simplicity of the 
Ziptip assay and the increasing availability of mass spectrometers capable of 
acquiring high resolution, isotopically-resolved data enables such analyses to 
become  routine,  simplifying  the  characterization  of  proteins  and  their 
modifications.  
The high expression level of mutant SOD1 in the transgenic animals 
was part of the original rationale to try mass spectrometry to detect SOD1 from 
spinal cord, but we also routinely observe other abundant proteins from tissue, 
such as ubiquitin and the endogenous rat SOD1 in the course of our assays. 
This represents the other major impact of the work in this dissertation. We 
have described a series of methods that enable the determination of protein 
metal-binding at the subunit level from in vivo samples. This is an important 
advantage over other techniques such as ICP-MS that rely on complete acid 
digestion of samples and therefore yield only solution measurements of the 
metals. Knowing which metals are specifically bound to a protein is crucial for 114 
 
understanding how the metals impact the structure and function of the protein 
in vivo. 
Chapter  4  revealed  significant  information  about  the  role  of  partially 
unfolded intermediates of SOD1 in ALS. The asymptomatic wild-type SOD1 
mice contained more partially unfolded intermediate SOD1 species than the 
G93A mice except for copper-containing, zinc-deficient SOD1. Zinc-containing 
SOD1 and disulfide reduced SOD1 were higher in wild-type spinal cords and 
brains, indicating that a model of toxicity that entails the formation of partially 
unfolded  species  leading  to  aggregation  is  not  sufficient  to  explain  the 
disease. The metal-binding clearly plays a substantial role in the stability of the 
protein and altered metal-binding forms of SOD1 are toxic to motor neurons, 
yet  the  metals  receive  far  less  attention.  Part  of  the  reason  for  this  is  the 
difficulty  of  measuring  the  specific  metal-binding  of  a  protein  from  in  vivo 
samples. Some groups have determined average metal-binding of SOD1 from 
whole  tissue,  most  notably  Lelie  et  al.,  who  used  size-exclusion 
chromatography leading to ICP-MS to determine the metal-binding of SOD1 
from transgenic tissue [104]. The data were presented as metal occupancy per 
SOD1 dimer. They found roughly 3.0 zinc ions and 1.0 copper ion per dimer of 
SOD1. The numbers we present in Chapter 4 are generally in good agreement 
with the occupancy they reported. However, what is not clear from Lelie et al. 
is the exact distribution of the metals in SOD1 subunits.  
Quantitative  measurements  of  the  partially  unfolded  intermediate 
species of SOD1 present in the spinal cord are absolutely essential to any 
determination  of  which  misfolded  intermediate  is  toxic  and  the  mechanism 
through  which  the  intermediate  exerts  toxicity.  We  have  now  quantitatively 
measured  for  the  first  time  the  levels  of  the  various  partially  unfolded 
intermediates  present  in  disease-affected  tissue  regions  as  the  disease 
develops.  More  specifically,  we  have  shown  that  a  small  amount  of  zinc-
deficient SOD1 is present in the G93A mouse spinal cord and that the level is 115 
 
significantly more than the control wild-type mice. This adds to the evidence 
that zinc-deficient SOD1 plays a role in the development of the disease. The 
amount of zinc-deficient SOD1 appears to be sufficient to be toxic in G93A 
spinal cord, but is generally below the toxic threshold in wild-type SOD1 mice. 
Zinc-deficient SOD1 functioning as the source of toxicity for ALS is not 
immediately apparent from the data presented in my dissertation. The G93A 
mice contain more zinc-deficient SOD1 than the wild-type mice, but they also 
maintain this level over much of their lifespan, including a significant portion 
where they do not display overt symptoms. The translation from the mice to 
human cases of the disease also becomes difficult. Since humans need only a 
single copy of mutant SOD1 to acquire the disease, the proportions in the 
mice would yield substantially less zinc-deficient SOD1, possibly an amount 
below the toxic threshold. I think the evidence for zinc-deficient SOD1 toxicity 
is too strong to ignore, which therefore suggests that the mechanism entails 
several more factors involved in the process. The participation of nitric oxide 
has already been elucidated, but the process to arrive at zinc-deficient SOD1 
in  the  first  place  is  still  nebulous  and  could  involve  a  number  of  factors. 
Although it has become somewhat of a punch line in the lab, the idea that ALS 
etiology is significantly more complex and involves more factors than just zinc-
deficient SOD1 (or SOD1 aggregates) is consistent with the human forms of 
the disease, which can display a wide range of onset ages and progression 
times that I suspect will be poorly correlated with any single factor. Additional 
experiments to elucidate the other players in ALS are therefore crucial.  
    
5.3 Future Research 
   
Like many experiments, the results of my dissertation research have 
produced additional questions that are worth pursuing further. With the tools 
developed  in  chapters  2  and  3,  we  can  now  investigate  several  questions 116 
 
about the role of SOD1 in ALS and what other factors may impact the disease 
progression. I describe four areas needing further investigation below. 
 
5.3.1 The Role of CCS 
  How CCS impacts and modulates SOD1-mediated ALS progression is 
not entirely clear. CCS has been used as evidence both for and against the 
zinc-deficient  SOD1  hypothesis.  CCS null G93A  mice  had  lower  enzymatic 
activity, which the authors extended to mean lower copper incorporation, and 
yet  the  same  disease  onset  and  progression.  This  became  evidence  that 
copper cannot be involved in the disease, despite the protein retaining 20% of 
its  activity.  On  the  other  side,  CCS  overexpressing  G93A  mice  had  a 
dramatically  faster  disease  onset  and  progression.  Whether  this  is  from 
increased copper incorporation is not yet clear. However, we now have the 
methods to address this by measuring the metal-binding of SOD1 and directly 
determine how the distribution of the metal-binding changes in response to 
CCS  overexpression.  Jared  Williams  has  in  fact  begun  looking  at  a  cross 
between the CCS overexpressing mice first described by Son, et al. [32], and 
our  G93A  mice,  G6SJL-Tg(SOD1*G93A)1Gur/J,  which  normally  develop 
symptoms around 100-110 days old and are terminal at 120-130 days old. 
Preliminary results show that the double transgenic animals display symptoms 
as  early  as  eight  days  old  and  become  terminal  before  15  days  old. 
Furthermore,  the  cross  of  the  CCS  mice  with  the  wild-type  SOD1 
overexpressing mice results in animals that also show neurological symptoms 
around  10-14  days  old,  a  phenomenon  that  Son  et  al.  did  not  observe. 
Determining how CCS changes the metal-distribution in SOD1 may help us to 
understand how the toxic gain of function originates.  
  An additional facet of this project is that CCS is important not only for 
insertion of copper into SOD1, but also for modulating the status of SOD1’s 
disulfide bond. Son et al., in further characterizing the CCS-SOD1 transgenic 117 
 
crosses, have described an increase in the amount of G93A disulfide reduced 
protein, while the opposite was true in the wild-type SOD1 mice [32,50]. The 
data  presented  in  this  dissertation  would  seem  to  suggest  that  disulfide 
reduction is not related to the disease, as the non-disease affected wild-type 
mice  had more  SOD1  with  a  reduced  disulfide.  However,  this still requires 
more  investigation.  CCS  overexpression  provides  a  way  to  influence  the 
SOD1 disulfide, and with the tools developed in this dissertation we have the 
methods necessary to monitor the disulfide bond of each metal-state of SOD1. 
 
5.3.2 Glutathione, Diamide, and Zinc-deficient SOD1 
  Another  molecule  that  may  play  a  role  in  ALS  is  the  abundant 
antioxidant glutathione. I observed the impact that glutathione could have on 
the metal-binding of SOD1 during my first summer in the lab. I was initially 
testing it to see if reduction of the SOD1 disulfide bond by glutathione could 
lead to loss of the zinc and thus a zinc-deficient SOD1 species. I did indeed 
see loss of the zinc ion; however, concurrent with zinc-loss I observed copper 
loss leading to the apo protein. We speculated that this was due to the ability 
of glutathione to chelate copper; however I was moving on to other labs for 
rotations  and  did  not  further  pursue  this  idea.  The  concept  returned  while 
gathering  the  data  for  chapter  4.  Initially,  we  could  not  measure  any  zinc-
deficient  SOD1  in  G93A  mouse  spinal  cord.  Upon  further  investigation  we 
found that a small-molecule present in the tissue homogenate appeared to be 
pulling copper out of zinc-deficient SOD1, an activity we could partially prevent 
by including the thiol oxidant diamide in the buffer. This has led to the idea that 
glutathione  may  be  able  to  prevent  zinc-deficient  SOD1-mediated  toxicity. 
Additional evidence for this is the effect of knock out of the γ-glutamylcysteine 
ligase modulatory subunit (GCLM) on G93A SOD1 mice lifespan, which die at 
50-60 days of age when GCLM is knocked out. This acceleration of disease 
progression may be due to the 80% reduction in glutathione that results from 118 
 
GCLM knockout. We have collected data from the spinal cords of two GCLM
-/-
xG93A SOD1 transgenic mice, and were able to measure a significant amount 
of  copper-containing,  zinc-deficient  SOD1  even  with  a  10-fold  reduction  in 
diamide concentration. These results suggest that glutathione may be a potent 
modulator  of  ALS  disease  progression,  either  through  its  ability  to  chelate 
copper,  influence  the  oxidation  status  of  the  disulfide  bond  of  SOD1,  or 
function as an antioxidant.  
  Elucidating the role of glutathione in ALS progression may also help to 
define the interactions between motor neurons and the surrounding cells such 
as astrocytes. Astrocytes can become reactive over the course of the disease, 
and have been shown to be toxic to motor neurons if exposed to zinc-deficient 
SOD1.  Whether  the  toxicity  originates  in  the  astrocytes  or  in  the  motor 
neurons in vivo, however, is not clear. Motor neurons are generally reliant on 
astrocytes to provide precursors for glutathione synthesis, and this may be 
one of the connections between the two cell types that could explain how zinc-
deficient SOD1 in the motor neurons leads to reactive astrocytes and motor 
neuron  death.  The  GCLM
-/-  G93A  SOD1  mice  are  an  important  model  for 
determining what role glutathione has and whether or not it could serve as a 
therapeutic agent. We have plans to acquire more of these animals; however 
the breeding necessary to generate them is substantial and thus it will take 
significantly more time before we have them available. 
 
5.3.3 Laser Capture Microdissection to look at Motor Neurons 
  A concern with the methods described in this dissertation is the level of 
dilution that the SOD1 from motor neurons undergoes by the time we are able 
to observe it. The punch method described in Chapter 2 is an improvement 
over the more common methods involving homogenization of an entire spinal 
cord as we are extracting specifically disease affected areas of the spinal cord, 
a  distinction  that  is  lost  when  the  whole  cord  is  used.  Motor  neurons  are 119 
 
known  to  be  particularly  rich  in  SOD1  [149],  yet  the  ventral  spinal  cord 
contains a heterogeneous cell population and the SOD1 we observe cannot 
be assumed to only reflect the distribution in motor neurons. It is possible that 
the amount  of  zinc-deficient  SOD1  we find is an  underestimate  due  to  the 
contribution  of  SOD1  from  other  cell  types  (astrocytes,  microglia,  etc.). 
Addressing this requires being able to extract only motor neurons from the 
spinal  cord  of  transgenic  mice,  an  ability  that  Oregon  State  University  has 
recently  acquired  with  the  purchase  of  a  laser  capture  microdissection 
instrument. With a demonstration model, we were able to measure SOD1 from 
approximately  200  cells  using  the  Ziptip  assay.  The  cells  so  extracted 
contained more zinc-deficient SOD1 than we have seen in the conventional 
tissue punches. Advancing this ability will allow us to specifically monitor the 
metal-binding of SOD1 in only motor neurons or other cell types, enabling us 
to determine with significantly more accuracy how SOD1 causes toxicity to 
motor neurons. 
 
5.3.4 The Connection to Nitrated HSP90 
  The nitration of HSP90 potentially represents the putative downstream 
target of zinc-deficient SOD1 and peroxynitrite; however the pathway between 
SOD1 and HSP90 has yet to be fully elucidated. Nitrated HSP90 was one of 
several proteins identified from peroxynitrite-treated PC12 cells that were then 
tested to see if the nitration had any role in peroxynitrite-mediated cell death. 
Peroxynitrite-treated HSP90, upon delivery to cultured motor neurons, induced 
cell  death  in  60%  of  the  cells.  In  an  effort  to  understand  which  tyrosine 
residues  participated  in  this  toxicity  (HSP90  has  24  tyrosines),  Alvaro 
Estévez’s lab identified 5 tyrosines in the protein that were prone to nitration. 
Thanks  to  the  unnatural  amino  acid  incorporation  system  of  Ryan  Mehl, 
HSP90  could  be  generated  with  a  nitrotyrosine  residue  at  each  of  those 
locations.  I  was  able  to  participate  in  these  experiments  by  confirming  the 120 
 
incorporation  of  the  nitrotyrosine  at  the  desired  position  via  tandem  mass 
spectrometry.  Delivery  of  each  nitrated  form  to  cultured  motor  neurons 
revealed that only nitration at positions 33 or 56 was able to initiate cell death. 
Nitration of HSP90 at one of those two positions clearly causes the protein to 
gain a toxic function that results in a Fas-mediated cellular death cascade that 
appears to be distinct in motor neurons.  
HSP90 can become nitrated via peroxynitrite in vitro and in cell culture 
models  and  this  may  represent  a  mechanism  involved  in  ALS  disease 
progression.  What  remains  to  be  worked  out  is  the  direct  role  that  zinc-
deficient SOD1 might play in this pathway. Some of the preliminary work from 
Alvaro Estévez’s lab suggests that SOD1 and HSP90 may physically interact; 
such  proximity  would  potentially  facilitate  nitration.  Surface  plasmon 
resonance experiments have shown that CuZn SOD1 does not bind to HSP90, 
and that zinc-only SOD1 binds weakly. Importantly, copper-containing zinc-
deficient SOD1 binds quite strongly, with 20 nM affinity. HSP90 is an abundant 
cellular protein, thus the levels of zinc-deficient SOD1 we have found in the 
spinal cord (~800 nM) are certainly sufficient for this interaction to happen in 
vivo. Determining if the interaction does indeed happen in vivo, and what the 
consequences are for motor neurons, represents the next step in the research. 
Now that we have a quantitative picture of the partially unfolded intermediates 
present in the cell throughout disease development, the interactions between 
HSP90 and all of those intermediates can be probed to determine if any of the 
interactions results in toxicity. 
 
5.4 Final Thoughts 
 
  My dissertation work has consisted of development of methods to 
measure the specific, subunit-level protein binding of two similar metals. I then 
applied that methodology to determine the distribution of the partially unfolded 121 
 
intermediate species of SOD1 from the spinal cord of transgenic, SOD1-
overexpressing ALS-model mice. This work has generated several novel 
methods that can be applied to other proteins and small-mass-difference 
protein modifications. Finally, we now have a detailed look at the potential 
involvement of differential metal-binding in ALS disease progression, opening 
many new avenues for research. 
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